

Publications of Department of Medicine in 2024

A. Refereed Papers Included in Science Citation Index:

- ¹: 表此篇文章以榮總之名義發表。
²: 表此篇文章以榮總及陽明之名義發表。
³: 表此篇文章為國外進修時之著作。
⁴: 表此篇文章之第一作者為本部其它科之醫師。
⁵: 表此篇文章之第一作者為本院其它部科或他院之醫師。
*: 為通訊作者
#: Equal contribution

Gastroenterology

1. ^{1,5}Balcar L, Scheiner B, Fulgenzi CAM, D'Alessio A, Pomej K, Roig MB, Meyer EL, Che J, Nishida N, Lee PC, Wu LD, Ang C, Krall A, Saeed A, Stefanini B, Cammarota A, Pressiani T, Abugabal YI, Chamseddine S, Wietharn B, Parisi A, Huang YH, Phen S, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, von Felden J, Schulze K, Silletta M, Trauner M, Samson A, Wege H, Piscaglia F, Galle PR, Stauber R, Kudo M, Singal AG, Itani A, Ulahannan SV, Parikh ND, Cortellini A, Kaseb A, Rimassa L, Chon HJ, Pinato DJ*, Pinter M*. A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma. *JHEP Rep* 2024;6(2):100982. (IF: 9.5)
2. ^{2,5}Celsa C, Cabibbo G, Fulgenzi CAM, Scheiner B, D'Alessio A, Manfredi GF, Nishida N, Ang C, Marron TU, Saeed A, Wietharn B, Pinter M, Cheon J, Huang YH, Lee PC, Phen S, Gampa A, Pillai A, Vivaldi C, Salani F, Masi G, Roehlen N, Thimme R, Vogel A, Schoenlein M, von Felden J, Schulze K, Wege H, Galle PR, Kudo M, Rimassa L, Singal AG, El Tomb P, Ulahannan S, Parisi A, Chon HJ, Hsu WF, Stefanini B, Verzoni E, Giusti R, Veccia A, Catino A, Aprile G, Guglielmini PF, Di Napoli M, Ermacora P, Antonuzzo L, Rossi E, Verderame F, Zustovich F, Ficorella C, Pietro FRD, Battelli N, Negrini G, Grossi F, Bordonaro R, Pipitone S, Banzi M, Ricciardi S, Laera L, Russo A, De Giorgi U, Cavanna L, Soraru M, Montesarchio V, Bordi P, Brunetti L, Pinto C, Bersanelli M, Camma C, Cortellini A, Pinato DJ*. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours. *J Hepatol* 2024;80(3):431-442. (IF: 26.8)
3. ^{2,4}Chang CC, Huang HC*, Hsu SJ*, Pun CK, Chuang CL, Hou MC, Lee FY. Ezetimibe treatment reduces oxidized low-density lipoprotein in biliary cirrhotic rats. *J Chin Med Assoc* 2024;87(5):463-470. (IF: 1.9)
4. ^{1,5}Chang CW, Hsu WF, Tseng KC, Chen CY, Cheng PN, Hung CH, Lo CC, Bair MJ, Chen CH, Lee PL, Lin CY, Kuo HT, Chen CT, Yang CC, Huang JF, Tai CM, Hu JT, Lin CL, Su WW, Tsai WL, Huang YH, Cheng CY, Lin CL, Wang CC, Yang SS, Mo LR, Chen GY, Chang CC, Wang SJ, Huang CS, Hsieh TY, Lin CW, Lee TH, Chong LW, Huang CW, Chang SN, Tsai MC, Hsu SJ, Kao JH, Liu CJ, Liu CH, Lin HC, Tsai PC, Yeh ML, Huang CF, Dai CY, Chuang WL, Yu ML*, Peng CY*. Benefits of Hepatitis C Viral Eradication: A Real-World Nationwide Cohort Study in Taiwan. *Dig Dis Sci* 2024;69(9):3501-3512. (IF: 2.5)

5. ^{2,4}Chang TE, Huang KH, Luo JC*, Huang YH, Lin HH, Fang WL, Hou MC. The alteration of fecal microbial and metabolic profile of gallstone patients in Taiwan: Single-center study. *J Chin Med Assoc* 2024;87(6):572-580. (IF: 1.9)
6. ^{2,5}Chang WL, Chen YF, Lee YH, Shiu MN, Chang PY, Guo CY, Huang CJ, Chiang CE, Chen CH, Chuang SY, Cheng HM*. Cardiovascular Risk in Patients With Treated Isolated Diastolic Hypertension and Isolated Low Diastolic Blood Pressure. *J Am Heart Assoc* 2024;13(8):e032771. (IF: 5.0)
7. ^{2,5}Chen WC, Yang TC, Lee PC, Wang YP, Hou MC*, Lee FY. A Randomized Controlled Trial of Propranolol Use During Ligation Program for Secondary Prophylaxis of Esophageal Variceal Bleeding. *Am J Gastroenterol* 2024;119(2):278-286. (IF: 8.5)
8. ^{2,5}Cheng PN, Chen WJ, Hou CJY, Lin CL, Chang ML, Wang CC, Chang WT, Wang CY, Lin CY, Hung CL, Peng CY, Yu ML, Chao TH, Huang JF, Huang YH, Chen CY, Chiang CE, Lin HC, Li YH, Lin TH, Kao JH, Wang TD, Liu PY, Wu YW*, Liu CJ*. Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction-associated fatty liver disease and cardiovascular diseases. *Clin Mol Hepatol* 2024;30(1):16-36. (IF: 14.0)
9. ^{2,5}Cheng SL, Lee HM, Li CP, Lin MW, Chou MY, Yen YT, Wu TH, Lian YC, Shih YC, Chiang CS, Chen TW*, Wan DH*, Chen YC*. Robust and Sustained STING Pathway Activation via Hydrogel-Based In Situ Vaccination for Cancer Immunotherapy. *ACS Nano* 2024;18(43):29439-29456. (IF: 15.8)
10. ^{2,5}Choi WM, Yip TCF, Kim WR, Yee LJ, Brooks-Rooney C, Curteis T, Clark LJ, Jafry Z, Chen CH, Chen CY, Huang YH, Jin YJ, Jun DW, Kim JW, Park NH, Peng CY, Shin HP, Shin JW, Yang YH, Wong GLH*, Lim YS*. Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-positive patients. *Hepatology* 2024;80(2):428-439. (IF: 13.0)
11. ^{2,5}Fulgenzi CAM, Scheiner B, D'Alessio A, Mehan A, Manfredi GF, Celsa C, Nishida N, Ang C, Marron TU, Wu LD, Saeed A, Wietharn B, Cammarota A, Pressiani T, Pinter M, Sharma R, Cheon J, Huang YH, Lee PC, Phen S, Gampa A, Pillai A, Napolitano A, Vivaldi C, Salani F, Masi G, Silletta M, Lo Prinzi F, Di Giacomo E, Vincenzi B, Bettinger D, Thimme R, Vogel A, Schoenlein M, von Felden J, Schulze K, Wege H, Galle PR, Pirisi M, Park JW, Kudo M, Rimassa L, Singal AG, El Tomb P, Ulahannan S, Parisi A, Chon HJ, Hsu WF, Ghittoni G, Camma C, Stefanini B, Trevisani F, Giannini EG, Cortellini A, Pinato DJ*. Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction. *JAMA Oncol* 2024;10(9):1253-1258. (IF: 22.3)
12. ²Ho CT, Fu CC, Tan ECH*, Kao WY, Lee PC, Huang YH, Huo TI, Hou MC, Wu JC, Su CW*. The association between proton-pump inhibitor use and recurrence of hepatocellular carcinoma after hepatectomy. *J Gastroenterol Hepatol* 2024;39(10):2077-2087. (IF: 3.7)
13. ²Ho CT, Tan ECH, Lee PC, Chu CJ, Huang YH, Huo TI, Hou MC, Wu JC, Su CW*. Prognostic Nutritional Index as a Prognostic Factor for Very Early-Stage Hepatocellular Carcinoma. *Clin Transl Gastroenterol* 2024;15(4):e00678. (IF: 3.2)
14. ²Ho CT, Tan ECH, Su CW*. Correspondence to editorial on "Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma". *Clin Mol Hepatol* 2024;30(4):1016-1018. (IF: 14.0)

15. ²Ho CT, Tan ECH*, Lee PC, Chu CJ, Huang YH, Huo TI, Su YH, Hou MC, Wu JC, Su CW*. Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma. *Clin Mol Hepatol* 2024;30(3):406-420. (IF: 14.0)
16. ²Ho CT*, Tan EH, Lee PC, Su CW. Reply to "Association between proton-pump inhibitor use and recurrence of hepatocellular carcinoma after hepatectomy: concerns to be addressed". *J Gastroenterol Hepatol* 2024;39(12):2942. (IF: 3.7)
17. ²Hsieh PH, Yang TC*, Kang EYN*, Lee PC, Luo JC, Huang YH, Hou MC, Huang SP. Impact of nutritional support routes on mortality in acute pancreatitis: A network meta-analysis of randomized controlled trials. *J Intern Med* 2024;295(6):759-773. (IF: 9.0)
18. ²Hsu SJ, Yang KY, Huang HC, Chuang CL, Chang CC*, Pun CK, Hou MC, Lee FY. Pre-treatment with tocilizumab reduces lipopolysaccharide-induced acute lung injury in biliary cirrhotic rats. *Eur J Pharmacol* 2024;980:176817. (IF: 4.2)
19. ^{2,5}Huang CC, Yeh HY, Lin R, Liao TL, Shen HC, Yang YY*, Lin HC. Inhibition of visceral adipose tissue-derived pathogenic signals by activation of adenosine A_{2A}R improves hepatic and cardiac dysfunction of NASH mice. *Am J Physiol-Gastroint Liver Physiol* 2024;326(4):G385-G397. (IF: 3.9)
20. ^{2,5}Huang JF, Chang TJ, Yeh ML, Shen FC, Tai CM, Chen JF, Huang YH, Hsu CY, Cheng PN, Lin CL, Hung CH, Chen CC, Lee MH, Lee CC, Lin CW, Liu SC, Yang H, Chien RN, Kuo CS, Peng CY, Chang ML, Huang CF, Yang YS, Yang HC, Lin HC, Ou HY, Liu CJ, Tseng CH, Kao JH, Chuang WL, Huang CN, Chen PJ, Wang CY*, Yu ML*. Clinical care guidance in patients with diabetes and metabolic dysfunction-associated steatotic liver disease: A joint consensus. *Hepatol Commun* 2024;8(11):e0571. (IF: 5.6)
21. ^{2,5}Hung YW, Lee IC, Chi CT, Lee RC, Liu CA, Chiu NC, Hwang HE, Chao Y, Hou MC, Huang YH*. Radiologic Patterns Determine the Outcomes of Initial and Subsequent Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma. *Liver Cancer* 2024;13(1):29-40. (IF: 11.6)
22. ^{2,5}Huo TI*, Ho SY. Preoperative MRI in predicting tumour recurrence of hepatocellular carcinoma: Does AI have a role?. *Liver Int* 2024;44(7):1739-1739. (IF: 6.0)
23. ^{2,5}Huo TI*, Ho SY. Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: A treatment dilemma. *Hepatol Res* 2024;54(12):1235. (IF: 3.9)
24. ^{1,5}Kim DS, Yoon YI, Kim BK, Choudhury A, Kulkarni A, Park JY, Kim J, Sinn DH, Joo DJ, Choi Y, Lee JH, Choi HJ, Yoon KT, Yim SY, Park CS, Kim DG, Lee HW, Choi WM, Chon YE, Kang WH, Rhu J, Lee JG, Cho Y, Sung PS, Lee HA, Kim JH, Bae SH, Yang JM*, Suh KS*, Al Mahtab M, Tan SS, Abbas Z, Shrestha A, Alam S, Arora A, Kumar A, Rath P, Bhavani R, Panackel C, Lee KC, Li J, Yu ML, George J, Tanwadee T, Hsieh SY, Yong CC, Rela M, Lin HC, Omata M, Sarin SK. Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation. *Hepatol Int* 2024;18(2):299-383. (IF: 5.9)
25. ^{2,5}Lai JI*, Kuo TH, Huang KJ, Chai LMX, Lee MH, Liu CY, Tsai YF, Huang CC, Tseng LM, Hsu CC*, Chao TC. Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients. *Oncologist* 2024;29(4):e455-e466. (IF: 4.8)
26. ²Lee IC, Tsai YP, Lin YC, Chen TC, Yen CH, Chiu NC, Hwang HE, Liu CA, Huang JG, Lee RC, Chao Y, Ho SY*, Huang YH*. A hierarchical fusion strategy of deep learning networks

- for detection and segmentation of hepatocellular carcinoma from computed tomography images. *Cancer Imaging* 2024;24(1):43. (IF: 3.5)
27. ^{2,5}Lee TL, Fang WC, Lee IC, Lirng JF, Chang CF, Hsu YB, Chu PY, Wang YF, Yang MH, Chang PMH, Wang LW, Tai SK*. Enhancing regional control in p16-negative oropharyngeal cancer: A propensity score-matched analysis of upfront neck dissection and definitive chemoradiotherapy. *J Chin Med Assoc* 2024;87(5):516-524. (IF: 1.9)
28. ^{2,5}Lee WP, Liao SX, Huang YH, Hou MC, Lan KH*. Akt1 is involved in HCV release by promoting endoplasmic reticulum-to-endosome transition of infectious virions. *Life Sci* 2024;338:122412. (IF: 5.2)
29. ^{2,5}Lee WP, Tsai KC, Liao SX, Huang YH, Hou MC, Lan KH*. Ser38-His93-Asn91 triad confers resistance of JFH1 HCV NS5A-Y93H variant to NS5A inhibitors. *FEBS J* 2024;291(6):1264-1274. (IF: 5.5)
30. ^{2,5}Lee WP, Tsai KC, Liao SX, Huang YH, Hou MC, Lan KH*. Ser235 phosphorylation of hepatitis C virus NS5A is required for NS5A dimerization and drug resistance. *Life Sci* 2024;337:122338. (IF: 5.2)
31. ²Li CJ, Lee PC*, Huang KW, Huang KJ, Chang TE, Chang CC, Wang SE, Shyr YM, Li CP, Luo JC, Hou MC. Postoperative prognostic nutrition index predicts survival in patients with small bowel adenocarcinoma after surgical resection. *J Chin Med Assoc* 2024;87(9):819-827. (IF: 1.9)
32. ²Li CJ*, Lee PC, Huang KW, Huang KJ, Chang TE, Chang CC, Wang SE, Shyr YM, Li CP, Luo JC, Hou MC. Reply to: Is "postoperative adjuvant chemotherapy" needed for small bowel adenocarcinoma after surgical resection?. *J Chin Med Assoc* 2024;87(12):1099-1100. (IF: 1.9)
33. ^{2,5}Li H, Chiang CL, Kwak KJ, Wang XY, Doddi S, Ramanathan LV, Cho SM, Hou YC, Cheng TS, Mo XK, Chang YS, Chang HL, Cheng WM, Tsai WN, Nguyen LTH, Pan JJ, Ma YF, Rima XY, Zhang JJ, Reategui E, Chu YS, Chang PMH, Chang PH, Huang CYF*, Wang CH*, Shan YS*, Li CP*, Fleisher M*, Lee LJ*. Extracellular Vesicular Analysis of Glypican 1 mRNA and Protein for Pancreatic Cancer Diagnosis and Prognosis. *Adv Sci* 2024;11(11):e2306373. (IF: 14.3)
34. ^{2,5}Li MY, Huang CF, Hung CH, Tai CM, Mo LR, Kuo HT, Tseng KC, Lo CC, Bair MJ, Wang SJ, Huang JF, Yeh ML, Chen CT, Tsai MC, Huang CW, Lee PL, Yang TH, Huang YH, Chong LW, Chen CL, Yang CC, Yang SS, Cheng PN, Hsieh TY, Hu JT, Wu WC, Cheng CY, Chen GY, Zhou GX, Tsai WL, Kao CN, Lin CL, Wang CC, Lin TY, Lin CL, Su WW, Lee TH, Chang TS, Liu CJ, Dai CY, Kao JH, Lin HC, Chuang WL, Peng CY, Wei-Tsai C, Chen CY*, Yu ML*. Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program. *Clin Mol Hepatol* 2024;30(1):64-79. (IF: 14.0)
35. ^{2,5}Liao HJ, Yang YP, Liu YH, Tseng HC, Huo TI, Chiou SH*, Chang CH*. Harnessing the potential of mesenchymal stem cells-derived exosomes in diseases. *Regen Ther* 2024;26:599-610. (IF: 3.4)
36. ^{2,5}Liao JI, Ho SY*, Hou MC, Liu PH, Hsu CY, Huo TI*. Performance status as a prognostic surrogate in hepatocellular carcinoma: Role of albumin-bilirubin and easy-albumin-bilirubin grade. *J Chin Med Assoc* 2024;87(2):156-162. (IF: 1.9)

37. ^{2,5}Lin CE, Chen CY*. Impacts of Central Administration of the Novel Peptide LEAP-2 in Different Food Intake Models in Conscious Rats. *Nutrients* 2024;16(12):1946. (IF: 4.8)
38. ²Lin KL, Sung KY, Ye YC, Wang YP*, Chang TE, Wu PS, Luo JC, Hou MC, Lu CL. Prolonged video capsule endoscopy examination durations can improve capsule endoscopy completeness. *BMC Gastroenterol* 2024;24(1):336. (IF: 2.5)
39. ^{2,5}Lin YH, Wang CH, Huang YH, Shen HC, Wu WK, Yeh HY, Huang CC, Su CW, Yang YY*, Wu MS, Lin HC, Hou MC. Models incorporating physical laboratory and gut metabolite markers can be used to predict severe hepatic steatosis in MAFLD patients. *Kaohsiung J Med Sci* 2024;40(12):1095-1105. (IF: 2.7)
40. ^{2,5}Liu TH, Chen SC, Rau KM, Lu LC, Lin PT, Su YY, Teng W, Lai SW, Yeh RH, Kao TM, Lee PC, Wu CJ, Chen CH, Hsu CH, Lin SM, Huang YH, Chen LT, Cheng AL, Shen YC*. Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma- with Emphasis on Locoregional Therapy for Oligoprogression. *Liver Cancer* 2024;13(5):509-521. (IF: 11.6)
41. ^{2,5}Lu CH, Wang W, Li YCJ, Chang IW, Chen CL, Su CW, Chang CC, Kao WY*. Machine Learning Models for Predicting Significant Liver Fibrosis in Patients with Severe Obesity and Nonalcoholic Fatty Liver Disease. *Obes Surg* 2024;34(12):4393-4404. (IF: 2.9)
42. ²Luan CH, Su PS, Chu CJ*, Lin CC, Su CW, Luo JC, Lee IC, Chi CT, Lee SD, Wang YJ, Lee FY, Huang YH, Hou MC. Analyzing risk factors and developing a stratification system for hepatocellular carcinoma recurrence after interferon-free direct-acting antiviral therapy in chronic hepatitis C patients. *J Chin Med Assoc* 2024;87(4):357-368. (IF: 1.9)
43. ^{2,5}Peng KW, Chang ML, Chien RN, Chen YC, Tian YC, Peng YS, Huang HC, Fang JT, Lee FY, Yang CW, Tsai MH*. Pulmonary Vascular Permeability and Extravascular Lung Water Index in Patients with Liver Cirrhosis and Septic Shock. *J Clin Med* 2024;13(13):3796. (IF: 3.0)
44. ²Pun CK, Huang HC, Chang CC, Chuang CL, Hsu SJ*, Hou MC, Lee FY. Fructooligosaccharides reverses hepatic vascular dysfunction and dysbiosis in rats with liver cirrhosis and portal hypertension. *Eur J Clin Invest* 2024;54(11):e14287. (IF: 4.4)
45. ²Pun CK, Huang HC, Chang CC, Hsu SJ*, Chuang CL, Huang YH, Hou MC, Lee FY. Low-dose alcohol exacerbates hyperdynamic circulation and shunting in non-alcoholic cirrhotic rats. *Biosci Rep* 2024;44(7):BSR20240354. (IF: 3.8)
46. ²Pun CK, Huang HC, Chang CC, Hsu SJ*, Huang YH, Hou MC, Lee FY. Hepatic encephalopathy: From novel pathogenesis mechanism to emerging treatments. *J Chin Med Assoc* 2024;87(3):245-251. (IF: 1.9)
47. ^{2,5}Shen HC, Pan MH, Huang CJ, Yeh HY, Yang H, Lin YH, Huang CC, Lee KC, Yang YY*, Hou MC. Multiple genetic polymorphisms are associated with the risk of metabolic syndrome fatty liver and airflow limitation: A Taiwan Biobank study. *Gene* 2024;927:148660. (IF: 2.6)
48. ^{2,5}Shen HC, Wang CH, Yang CW, Lin YH, Yeh HY, Perng DW, Yang YY*, Hou MC. Elevated neutrophil-to-lymphocyte ratio combined with decreased lymphocyte-to-monocyte ratio is associated with increased peripheral airway resistance in patients with hepatic steatosis. *Medicine (Baltimore)* 2024;103(26):e38530. (IF: 1.4)
49. ^{2,5}Shen YC, Liu TH, Nicholas A, Soyama A, Yuan CT, Chen TC, Eguchi S, Yoshizumi T, Itoh S, Nakamura N, Kosaka H, Kaibori M, Ishii T, Hatano E, Ogawa C, Naganuma A, Kakizaki

- S, Cheng CH, Lin PT, Su YY, Chuang CH, Lu LC, Wu CJ, Wang HW, Rau KM, Hsu CH, Lin SM, Huang YH, Hernandez S, Finn RS, Kudo M, Cheng AL*. Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab. *J Clin Oncol* 2024;42(34):4060-4070. (IF: 42.1)
50. ^{2,4}Su CW, Ochirkhuree B, Namdag B, Badamnachin B, Ganbold S, Gidaagaya S, Ganbold A, Yang SS, Duger D*, Wu JC*. Risk factors associated with hepatitis D virus infection and preventive strategies in Mongolia. *J Chin Med Assoc* 2024;87(5):480-487. (IF: 1.9)
 51. ^{2,5}Su YY, Chiang NJ, Chiu TJ, Huang CJ, Hsu SJ, Lin HC, Yang SH, Yang YS, Chou WC, Chen YY, Bai LY, Li CP*, Chen JS*. Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation. *Biomed J* 2024;47(3):100696. (IF: 4.1)
 52. ^{2,5}Sun C, Goh GBB, Chow WC, Chan WK, Wong GLH, Seto WK, Huang YH, Lin HC, Lee IC, Lee HW, Kim SU, Wong VWS*, Fan JG*. Prevalence and risk factors for impaired renal function among Asian patients with nonalcoholic fatty liver disease. *Hepatob Pancreatic Dis Int* 2024;23(3):241-248. (IF: 3.6)
 53. ^{2,5}Tang CY, Yang SH, Li CP, Su YY, Chiu SC, Bai LY, Shan YS, Chen LT, Chuang SC, Chan DC, Yen CJ, Peng CM, Chiu TJ, Chen YY, Chen JS, Chiang NJ*, Chou WC*. Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer. *Pancreatology* 2024;24(3):600-607. (IF: 2.8)
 54. ^{2,5}Teng W, Chang TT, Yang H, Peng CY, Su CW, Su TH, Hu TH, Yu ML, Yang HC, Wu JW*. Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines (vol 15 pg 1421 2021). *Hepatol Int* 2024;18(3):1066-1066. (IF: 5.9)
 55. ^{2,5}Tsai CF, Chuang CH, Tu PC, Chang WC, Wang YP, Liu PY, Wu PS, Lin CY, Lu CL*. Interaction of the gut microbiota and brain functional connectivity in late-life depression. *J Psychiatry Neurosci* 2024;49(5):E289-E300. (IF: 4.1)
 56. ^{2,5}Tsai PC, Huang CF, Yeh ML, Hsieh MH, Kuo HT, Hung CH, Tseng KC, Lai HC, Peng CY, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Kao JH, Liu CJ, Liu CH, Yan SL, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Tai CM, Lin CW, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Chen CY, Huang JF, Dai CY, Chung WL, Bair MJ*, Yu ML*. Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy. *Clin Mol Hepatol* 2024;30(3):468-486. (IF: 14.0)
 57. ^{2,5}Tsai YL, Chung MH, Lin NC, Chen CY, Lin YP, Tsai MT, Tsai HL, Chen YA, Ou SM*, Chu CJ, Wu TH*, Tsai CY. The Risk Factors and Clinical Outcomes in Hepatitis B Seropositive and Seronegative Renal Transplant Patients. *Am J Nephrol* 2024;55(4):477-486. (IF: 4.3)
 58. ^{2,5}Wu KC, Lee IC*, Chi CT, Liu CA, Chiu NC, Hsu SJ, Lee PC, Wu CJ, Luo JC, Hou MC, Huang YH. Impact of HCV eradication on recurrence pattern and long-term outcomes in patients with HCV-related hepatocellular carcinoma undergoing radiofrequency ablation. *Aliment Pharmacol Ther* 2024;60(7):940-952. (IF: 6.6)
 59. ^{2,5}Wu KC, Lee IC*, Liu CA, Chiu NC, Hsu SJ, Lee PC, Wu CJ, Chi CT, Luo JC, Hou MC, Huang YH. Diabetes Mellitus Negatively Impacts Outcomes of HBV-Related Hepatocellular Carcinoma Following Thermal Ablation. *J HEPATOCELL CARCINOMA* 2024;11():2257-2267. (IF: 4.2)

60. ^{2,4}Wu PS, Hsieh YC, Lee PC, Yang TC, Chen YJ, Yang YY, Huang HC, Hsu SJ, Huo TI, Lee KC*, Lin HC, Hou MC*. Mac-2-Binding Protein Glycosylation Isomer to Albumin Ratio Predicts Bacterial Infections in Cirrhotic Patients. *Dig Dis* 2024;42(2):166-177. (IF: 2.0)
61. ^{2,5}Wu YH, Shen SH, Wang YP, Chang NW, Lee PC, Li CP, Lan KL, Shiau CY, Hu YW, Huang PI, Hsu CX, Yen SH, Hsu SM*. Feasibility estimation of injected hydrodissection before definitive radiotherapy of pancreatic adenocarcinoma. *J Chin Med Assoc* 2024;87(5):511-515. (IF: 1.9)
62. ^{2,5}Yang CC, Huang CF, Chang TS, Lo CC, Hung CH, Huang CW, Chong LW, Cheng PN, Yeh ML, Peng CY, Cheng CY, Huang JF, Bair MJ, Lin CL, Yang CC, Wang SJ, Hsieh TY, Lee TH, Lee PL, Wu WC, Lin CL, Su WW, Yang SS, Wang CC, Hu JT, Mo LR, Chen CT, Huang YH, Chang CC, Huang CS, Chen GY, Kao CN, Tai CM, Liu CJ, Lee MH, Kuo HT, Tsai PC, Dai CY, Kao JH, Lin HC, Chuang WL, Tseng KC, Chen CY*, Yu ML*. Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naive Patients from a Nationwide HCV Registry in Taiwan. *Infect Dis Ther* 2024;13(6):1199-1213. (IF: 4.7)
63. ²Yang TC, Chen WC, Hou MC*, Chen PH, Lee PC, Chang CY, Lu HS, Chen YJ, Hsu SJ, Huang HC, Luo JC, Huang YH, Lee FY. Endoscopic variceal ligation versus propranolol for the primary prevention of oesophageal variceal bleeding in patients with hepatocellular carcinoma: an open-label two-centre randomised controlled trial. *Gut* 2024;73(4):682-690. (IF: 23.1)
64. ²Ye YC, Sung KY, Chang TE, Wu PS, Wang YP*, Luo JC, Hou MC, Lu CL. Early double-balloon enteroscopy was not related to better clinical outcomes in patients with suspected overt small bowel bleeding. *J Chin Med Assoc* 2024;87(4):377-383. (IF: 1.9)
65. ²Ye YC, Wang YP*, Chang TE, Wu PS, Hsin IF, Chen PH, Tai SK, Chu PY, Hou MC, Lu CL. Routine image-enhanced endoscopic surveillance for metachronous esophageal squamous cell neoplasms in head and neck cancer patients. *Esophagus* 2024;21(2):131-140. (IF: 2.2)
66. ^{2,5}Yeh HY, Wu HTH, Shen HC, Li TH, Yang YY*, Lee KC, Lin YH, Huang CC, Hou MC. Optimal body mass index for protecting middle-aged and elderly patients with fatty liver from future fractures. *Endocr Connect* 2024;13(8):e240089. (IF: 2.6)
67. ^{2,5}Yen FS, Hou MC, Wei JCC, Shih YH, Hsu CY, Hsu CC*, Hwu CM*. Glucagon-like Peptide-1 Receptor Agonist Use in Patients With Liver Cirrhosis and Type 2 Diabetes. *Clin Gastroenterol Hepatol* 2024;22(6):1255-1264.e18. (IF: 11.6)
68. ^{2,5}Yen FS, Hou MC, Wei JCC, Shih YH, Hwu CM*, Hsu CC*. Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes. *BMC Med* 2024;22(1):29-40. (IF: 7.1)
69. ^{2,5}Yu ML, Tai CM, Mo LR, Kuo HT, Huang CF, Tseng KC, Lo CC, Bair MJ, Wang SJ, Huang JF, Yeh ML, Chen CT, Tsai MC, Huang CW, Lee PL, Yang TH, Huang YH, Chong LW, Chen CL, Yang CC, Hung CH, Yang SS, Cheng PN, Hsieh TY, Hu JT, Wu WC, Cheng CY, Chen GY, Zhou GX, Tsai WL, Kao CN, Lin CL, Wang CC, Lin TY, Lin CL, Su WW, Lee TH, Chang TS, Liu CJ, Dai CY, Chen CY, Kao JH, Lin HC, Chuang WL, Peng CY*. An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan. *Hepatol Int* 2024;18(2):461-475. (IF: 5.9)

Cardiology

1. ^{1,5}Allamsetty S, Lin CY*, Lin YJ, Chen SA. Spontaneous Conversion of a Long RP to Short RP Tachycardia: What Is the Mechanism? *PACE-Pacing Clin Electrophysiol* 2024; 47(12):1611-1613. (IF:1.7)
2. ^{2,5}Bucci T, Nabrdalik K, Shantsila A, Romiti GF, Teo WS, Park HW, Shimizu W, Tse HF, Proietti M, Chao TF, Lip GYH*. Adverse Events and Clinical Correlates in Asian Patients with Atrial Fibrillation and Diabetes Mellitus: A Report from Asia Pacific Heart Rhythm Society Atrial Fibrillation Registry. *J Clin Med* 2024; 13(5):1274. (IF:3.0)
3. ^{2,5}Bucci T, Romiti GF, Shantsila A, Teo WS, Park HW, Shimizu W, Corica B, Proietti M, Tse HF, Chao TF*, Frost F, Lip GYH*. Risk of Death and Cardiovascular Events in Asian Patients With Atrial Fibrillation and Chronic Obstructive Pulmonary Disease: A Report From the Prospective APHRS Registry. *J Am Heart Assoc* 2024; 13(7):e032785. (IF:5.0)
4. ^{2,5}Bucci T, Romiti GF, Corica B, Shantsila A, Teo WS, Park HW, Shimizu W, Tse HF, Proietti M, Chao TF, Lip GYH*. Educational status and the risk of adverse outcomes in Asian patients with atrial fibrillation: a report from the prospective APHRS-AF Registry. *Minerva Med* 2024; 115(3):308-319. (2023: JCR Suppressed Journal)
5. ^{2,5}Chan YH, Chao TF, Chen SW, Lee HF, Li PR, Yeh YH, Kuo CT, See LC*, Lip GYH. SGLT2 Inhibitors vs GLP-1 Receptor Agonists and Clinical Outcomes in Patients With Diabetes With/Without Atrial Fibrillation. *J Clin Endocrinol Metab* 2024; 109(10):2617-2629. (IF: 5.0)
6. ^{2,5}Chan YH, Chen SW, Chan CY, Chao TF*. Comparative safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation: A network meta-analysis. *J Formos Med Assoc* 2024; 123(5): 578-586. (IF:2.6)
7. ^{2,5}Chan YH, See LC, Chao TF*. Reply to Letter to the Editor by Thompson et al. *EUR. HEART J.-CARDIOVASC. PHARMACOTHER* 2024; 10(4):365. (IF:5.4)
8. ²Chang CC*, Sung WT, Lu YW, Chuang MJ, Lee YH, Tsai YL, Chou RH, Huang SS, Huang PH*. Real-World Clinical Performance of a Novolimus-Eluting Stent Versus a Sirolimus-Eluting Stent. *Clin Cardiol* 2024; 47(7): e24317. (IF:2.4)
9. ^{1,5}Chang GJ, Chen WJ*, Hsu YJ, Chen YH. Empagliflozin Attenuates Neointima Formation After Arterial Injury and Inhibits Smooth Muscle Cell Proliferation and Migration by Suppressing Platelet-Derived Growth Factor-Related Signaling. *J Am Heart Assoc* 2024; 13(22): (IF:5.0)
10. ^{2,5}Chang HC, Chen YY, Kuo TT, Lin YJ, Chien KL, Chang HY, Hung CL*, Chung FP*. Sodium Glucose Transporter 2 Inhibitors Versus Metformin on Cardiovascular and Renal Outcomes in Patients With Diabetes With Low Cardiovascular Risk: A Nationwide Cohort Study. *J Am Heart Assoc* 2024; 13(8): e032397. (IF:5.0)
11. ²Chang HC, Kuo L, Sung SH, Niu DM, Yu WC*. Prognostic Implications of Left Ventricular Hypertrophy and Mechanical Function in Fabry Disease: A Longitudinal Cohort Study. *J Am Soc Echocardiogr* 2024; 37(8):787-796. (IF: 5.4)
12. ^{2,5}Chang HY, Lee CM, Hung CL, Sung SH, Lin TH, Wu YW, Hwang JJ, Chen WJ, Wang CC*. Taiwan Society of Cardiology Heart Failure Registry 2020: Rationale and Design. *Acta Cardiol Sin* 2024; 40(2): 235-241. (IF: 1.8)
13. ^{2,5}Chang LH, Chang TT, Chu CH, Huang CC, Lin LY*. Soluble tumor necrosis factor receptor type 1 is an alternative marker of urinary albumin-creatinine ratio and estimated glomerular filtration rate for predicting the decline of renal function in subjects with type 2 diabetes

- mellitus. Clin Chim Acta 2024;558:117880. (IF:3.2)
14. ^{2,5}Chang LY, Chao CY, Huang JL, Chen YY, Wang CY, Lee WL, Lin WW*. Impact of the Coronavirus Disease 2019 [COVID-19] Pandemic on Post-Acute Care of Patients with Heart Failure and the Effectiveness of Vaccine Prevention. Healthcare 2024; 12(21):2171. (IF:2.4)
 15. ^{2,5}Chang TT*, Li YZ, Mo HW, Chen C, Lin LY, Chang CC, Chen JW. Inhibition of CCL7 improves endothelial dysfunction and vasculopathy in mouse models of diabetes mellitus. Sci Transl Med 2024; 16(763): eadn1507. (IF:15.8)
 16. ^{2,5}Chang TT, Lin LY, Chen C, Chen JW. CCL4 contributes to aging related angiogenic insufficiency through activating oxidative stress and endothelial inflammation. Angiogenesis 2024; 27(3):475-499. (IF:9.2)
 17. ^{2,5}Chang WL, Chen YF, Lee YH, Shiu MN, Chang PY, Guo CY, Huang CJ, Chiang CE, Chen CH, Chuang SY, Cheng HM*. Cardiovascular Risk in Patients With Treated Isolated Diastolic Hypertension and Isolated Low Diastolic Blood Pressure. J. Am. Heart Assoc. 2024; 13(8): e032771. (IF:5.0)
 18. ^{1,5}Chao CJ, Jeong J, Arsanjani R, Kim K, Tsai YL, Yu WC, Farina JM, Mahmoud AK, Ayoub C, Grogan M, Kane GC, Banerjee I, Oh JK*. Echocardiography-Based Deep Learning Model to Differentiate Constrictive Pericarditis and Restrictive Cardiomyopathy. JACC-Cardiovasc Imag 2024;17(4):349-360. (IF: 12.8)
 19. ²Chao TF, Potpara TS, Lip GYH. Atrial fibrillation: stroke prevention. Lancet Reg Health-Eur 2024; 37 (11):1765-1774. (IF:13.600)
 20. ²Chao TF*, Yeh YH, Chan YH, Lin FJ, Chen TH, Pan KL, Lin JC, Lin YJ, Chen SA. The Report of Community-Based and Government-Endorsed Screening Program of Atrial Fibrillation in Taiwan. Thromb Haemost 2024; 124(01): 61-68. (IF: 5.0)
 21. ^{2,5}Chao TH*, Lin TH, Cheng C, Wu YW, Ueng KC, Wu YJ, Lin WW, Leu HB, Cheng HM, Huang CC, Wu CC, Lin CF, Chang WT, Pan WH, Chen PR, Ting KH, Su CH, Chu CS, Chien KL, Yen HW, Wang YC, Su TC, Liu PY, Chang HY, Chen PW, Jimmy JM, Lu YW, Lin PL, Wang CP, Ko YS, Chiang CE, Hou CJY, Wang TD, Lin YH, Huang PH, Chen WJ. 2024 Guidelines of the Taiwan Society of Cardiology on the Primary Prevention of Atherosclerotic Cardiovascular Disease --- Part II. Acta Cardiol Sin 2024; 40(6): 669-715. (IF: 1.8)
 22. ^{2,5}Chao TH*, Lin TH, Cheng C, Wu YW, Ueng KC, Wu YJ, Lin WW, Leu HB, Cheng HM, Huang CC, Wu CC, Lin CF, Chang WT, Pan WH, Chen PR, Ting KH, Su CH, Chu CS, Chien KL, Yen HW, Wang YC, Su TC, Liu PY, Chang HY, Chen PW, Jimmy JM, Juang JMJ, Lu YW, Lin PL, Wang CP, Ko YS, Chiang CE, Hou CJY, Wang TD, Lin YH, Huang PH, Chen WJ. 2024 Update of the TSOC Expert Consensus of Disease. Acta Cardiol Sin 2024; 40(5): 544-568. (IF: 1.8)
 23. ^{2,5}Chen CE, Guo JY, Chou RH*, Wu CH, Kuo CS, Wei JH, Huang PH*. Circulating corin concentration is associated with risk of mortality and acute kidney injury in critically ill patients. Sci Rep 2024; 14(1):19848. (IF:3.8)
 24. ^{2,5}Chen CY, Wang MT, Sung SH, Wu YJ, Hsu CH, Ho WJ, Lin YH, Liu WS, Liu JC, Kao YT, Wu WS, Wu CH, Lei MH, Chen YW, Chien CY, Chiu YW, Dai ZK, Lin TH, Lin L, Chung CC, Chung CM, Huang SH, Cheng CC, Wu YW, Chao TH, Hwang JJ, Hou CJY, Huang WC*. Exercise capacity-hemodynamics mismatch in elderly patients with pulmonary hypertension: A nationwide multicenter study from Taiwan Society of Cardiology Pulmonary Hypertension

- Registry (TAIPANS). *Heliyon* 2024; 10(6): 10(6):e27537. (IF: 3.4)
25. ^{2,5}Chen KH*, Hsu YY, Chou CY, Hsu CC, Chang SL, Yu WC, Chang YL*. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in low-weight patients with atrial fibrillation. *J Thromb Thrombolysis* 2024; 57(7):1268-1280. (IF: 2.3)
 26. ^{2,5}Chen KL, Chou RH*, Chang CC, Kuo CS, Wei JH, Huang PH*, Lin SJ. The high-density lipoprotein cholesterol (HDL-C)-concentration-dependent association between anti-inflammatory capacity and sepsis: A single-center cross-sectional study. *PLoS One* 2024; 19(4): e0296863. (IF:2.9)
 27. ^{2,5}Chen LC, Hung KH, Tseng YJ, Wang HY, Lu TM*, Huang WC*, Tsao Y*. Self-Supervised Learning-Based General Laboratory Progress Pretrained Model for Cardiovascular Event Detection. *IEEE J Transl Eng Health Med-JTEHM*. 2024; 12:43-55. (IF: 3.7)
 28. ^{2,5}Chen WT, Chung FP*, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chao TF, Liao JN, Lin CY, Chang TY, Kuo L, Wu C, Liu CM, Liu SH, Hsieh YC, Li CH, Chen SA. Lower contact force predicts right pulmonary vein carina breakthrough after ablation index-guided pulmonary vein isolation using high-power short-duration. *J Cardiovasc Electrophysiol* 2024; 35(1): 60-68. (IF: 2.3)
 29. ^{2,5}Chen WW, Liu CM, Tseng CC, Huang CC, Wu IC, Chen PF, Chang SL, Lin YJ, Lo LW, Chung FP, Chao TF, Tuan TC, Liao JN, Lin CY, Chang TY, Kuo L, Wu C, Liu SH, Wu JCH, Hu YF*, Chen SA*, Lu HHS*. Identifying the presence of atrial fibrillation during sinus rhythm using a dual-input mixed neural network with ECG coloring technology. *BMC Med Res Methodol* 2024; 24(1):318. (IF:3.9)
 30. ^{2,5}Chen Y, Gue Y, Calvert P, Gupta D, McDowell G, Azariah JL, Namboodiri N, Bucci T, Jabir A, Tse HF, Chao TF, Lip GYH*, Bahuleyan CG*. Predicting stroke in Asian patients with atrial fibrillation using machine learning: A report from the KERALA-AF registry, with external validation in the APHRS-AF registry. *Curr Probl Cardiol* 2024; 49(4):102456. (IF:3.0)
 31. ^{2,5}Chen YT, Lin CC, Huang PH*, Li SY*. Comparative analysis of hemodialysis and peritoneal dialysis on the risk of new onset diabetes mellitus. *J Formos Med Assoc* 2024; 123(5): 606-612. (IF: 2.6)
 32. ²Chen YY, Chang HC, Lin YJ*, Chien KL, Hsieh YC, Chung FP, Lin CH, Lip GYH, Chen SA. The impact of sodium-glucose co-transporter-2 inhibitors on dementia and cardiovascular events in diabetic patients with atrial fibrillation. *Diabetes-Metab Res Rev* 2024; 40(2):e3775. (IF:4.6)
 33. ^{1,5}Chen ZW, Liao CW, Pan CT, Tsai CH, Chang YY, Chang CC, Lee BC, Chiu YW, Huang WC, Lai TS, Lu CC, Chueh JS, Wu VC, Hung CS, Lin YH*. Reversal of arterial stiffness in medically and surgically treated unilateral primary aldosteronism. *J Hypertens* 2024; 42(3): 538-545. (IF: 3.3)
 34. ^{1,5}Cheng HC, Wu SFV, Chen YH, Tsan YH, Sung SH, Ke LS*. Advance Care Planning Affects End-of-Life Treatment Preferences Among Patients With Heart Failure. *J Hosp Palliat Nurs* 2024; 26(1):E13-E19. (IF:1.2)
 35. ^{2,5}Cheng PN, Chen WJ, Hou CJY, Lin CL, Chang ML, Wang CC, Chang WT, Wang CY, Lin CY, Hung CL, Peng CY, Yu ML, Chao TH, Huang JF, Huang YH, Chen CY, Chiang CE, Lin HC, Li YH, Lin TH, Kao JH, Wang TD, Liu PY, Wu YW*, Liu CJ*. Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the

- management of metabolic dysfunction-associated fatty liver disease and cardiovascular diseases. *Clin. Mol. Hepatol.* 2024; 30(1): 16-36. (IF:14.0)
36. ^{2,5}Cheng WH, Lo LW, Chou YH, Liu SH, Lin WL, Chen SA. Empagliflozin Ameliorates Atrial and Ventricular Remodeling and Arrhythmogenesis in an Overweight Rabbit Model. *Acta Cardiol Sin* 2024; 40(6):729-739. (IF: 1.8)
 37. ^{2,5}Chiang CH, Lan TY, Hsieh JH, Lin SC, Chen JW, Chang TT*. Diosgenin Reduces Acute Kidney Injury and Ameliorates the Progression to Chronic Kidney Disease by Modifying the NOX4/p65 Signaling Pathways. *J Agric Food Chem* 2024;72(31): 17444-17454. (IF: 5.7)
 38. ^{1,5}Chin CG, Chen YC, Lin FJ, Lin YK, Lu YY, Cheng TY, Chen SA, Chen YJ*. Targeting NLRP3 signaling reduces myocarditis-induced arrhythmogenesis and cardiac remodeling. *J Biomed Sci* 2024; 31(1):42. (IF:9.0)
 39. ²Chou RH, Yang SF, Huang PH*. Risks and Benefits of Continuing Renin-Angiotensin-Aldosterone System Inhibitors in Critically-Ill Patients. *Acta Cardiol Sin* 2024; 40(2): 260-261. (IF: 1.8)
 40. ^{2,5}Chuang MJ, Huang WC*, Chen YY, Lu TM. The Short-Term and One-Year Clinical Outcomes in Patients with Optical Coherence Tomography-Guided Magmaris Implantation: A Real-World Clinical Practice. *J Interv Cardiol* 2024; (IF: 1.6)
 41. ^{1,5}Chung YW, Cheng JF, Lin YL, Chuang HJ, Chuang CC, Chen CW, Huang WM, Wu CK*, Lin LY*. A non-invasive nomogram for predicting heart failure with preserved ejection fraction in taiwanese outpatients with unexplained dyspnea and fatigue. *J Formos Med Assoc* 2024;123(12): 1260-1266. (IF: 2.6)
 42. ^{2,5}Ciou WS, Wang CC, Lin FJ, Chao TF, Lin SY*. Comparison of different direct oral anticoagulant regimens in atrial fibrillation patients with high bleeding risk. *Heart Rhythm.* 2024; 21(6): 715-722. (IF: 6.34)
 43. ^{1,5}Conte G*, Bergonti M, Probst V, Morita H, Tfelt-Hansen J, Behr ER, Kengo K, Arbelo E, Crotti L, Sarquella-Brugada G, Wilde AAM, Calo L, Sarkozy A, de Asmundis C, Mellor G, Migliore F, Letsas K, Vicentini A, Levinstein M, Berne P, Chen SA, Veltmann C, Biernacka EK, Carvalho P, Kabawata M, Sojema K, Gonzalez MC, Tse G, Thollet A, Svane J, Caputo ML, Scrocco C, Kamakura T, Pardo LF, Lee SR, Juarez CK, Martino A, Lo LW, Monaco C, Reyes-Quintero AE, Martini N, Oezkartal T, Klersy C, Brugada J, Schwartz PJ, Brugada P, Belhassen B, Auricchio A. aTrial arrhythmias in inhEriTed aRrhythmIa Syndromes: results from the TETRIS study. *Europace* 2024;26(12):euae288. (IF: 7.9)
 44. ^{2,5}Corica B, Romiti GF, Proietti M, Mei DA, Boriani G, Chao TF, Olshansky B, Huisman MV, Lip GYH*. Clinical Outcomes in Metabolically Healthy and Unhealthy Obese and Overweight Patients With Atrial Fibrillation: Findings From the GLORIA-AF Registry. *Mayo Clin. Proc.* 2024; 99(6): 927-939. (IF: 6.9)
 45. ^{2,5}Fan HY, Hsu HY, Lin HJ, Chen YY, Chen YC, Su TC, Chien KL*. Systolic blood pressure as a critical mediator in the association between adult height and 25-year risk of stroke. *Obes. Res. Clin. Pract.* 2024; 18(2): 124-130. (IF:2.5)
 46. ⁵Goh RSJ, Chong B, Jayabaskaran J, Jauhari SM, Chan SP, Kueh MTW, Shankar K, Li H, Chin YH, Kong G, Anand VV, Chan KA, Sukmawati I, Toh SA, Muthiah M, Wang JW, Tse G, Mehta A, Fong A, Baskaran L, Zhong L, Yap J, Yeo KK, Hausenloy DJ, Tan JWC, Chao TF, Li YH, Lim SL, Chan KH, Loh PH, Chai P, Yeo TC, Low AF, Lee CH, Foo R, Tan HC,

- Yip J, Rao SI, Honda S, Yasuda S, Kajiya T, Goto S, Yan BP, Zhou X, Figtree GA, Mamas MA, Kim Y, Jeong YH, Kim MH, Park DW, Park SJ, Richards AM, Chan MY*, Lip GYH, Chew NWS*. The burden of cardiovascular disease in Asia from 2025 to 2050: a forecast analysis for East Asia, South Asia, South-East Asia, Central Asia, and high-income Asia Pacific regions. *Lancet Reg Health-W Pac* 2024; 10:49:101138. (IF: 7.6)
47. ²Ho IW, Kuo MJ, Hsu PF, Lee IH, Hsu TF, Lin YJ, Huang CC*. The impacts of anemia burden on clinical outcomes in patients with out-of-hospital cardiac arrest. *Clin Cardiol* 2024; 47(1):e24175. (IF:2.4)
 48. ^{2,4}Hsiao YW, Lin WL, Chou YH, Liu SH, Liao TWE, Chen SA*, Lo LW*. Renal sympathetic denervation ameliorates the activated inflammatory response through JAK-STAT pathway in a chronic obstructive sleep apnea animal model. *Sleep Med.* 2024; 113:142-151. (IF: 3.8)
 49. ²Hsu CJ, Wu C*, Lin YJ. A Case with a Short QT Interval and Idiopathic Ventricular Fibrillation Due to Carnitine Transporter Defect. *Acta Cardiol Sin* 2024;40(6):801-804. (IF: 1.8)
 50. ²Hsu CY, Chang SL*, Lin YJ, Lo LW, Hu YF, Chung FP, Lin CY, Chang TY, Chuang CM, Kou MJ, Chen WT, Chhay C, Kao PH, Ibrahim AE, Lin WS, Chen SA. Three-dimensional mapping and superior approach for catheter ablation in patients without inferior vena cava access. *PACE-Pacing Clin. Electrophysiol.* 2024;47(11):1507-1514. (IF: 1.7)
 51. ^{2,5}Hsu CY, Chung FP, Chao CJ, Chen YJ, Wu CK, Wu YW, Huang JL, Chu PH, Hou CJY, Chang HY*, Hung CL*. Efficacy of Sacubitril-Valsartan on Survival and Cardiac Remodeling in Hypotensive Heart Failure With Reduced Ejection Fraction: A Multicenter Study. *Mayo Clin Proc* 2024; 99(6): 940-952. (IF:7.2)
 52. ^{1,5}Huang B, Lam HM, Ishiguchi H, Liu Y, Chao TF, Olshansky B, Huisman M, Lip G. Temporal trends and regional differences of initial oral antiarrhythmic drug options in patients with new-onset atrial fibrillation: a report from the GLORIA-AF registry. *Eur Heart J* 2024; 45() (IF: 38.1)
 53. ^{2,5}Huang CC, Sung SH, Wang WT, Su YY, Huang CJ, Chu TY, Chuang SY, Chiang CE, Chen CH, Lin CC*, Cheng HM*. Examining arterial pulsation to identify and risk-stratify heart failure subjects with deep neural network. *Phys Eng Sc. Med* 2024; 47(2):477-489. (IF:2.4)
 54. ^{2,5}Huang CW, Tu KH, Fan KC, Tsai CH, Wang WT, Wang SY, Wu CY, Hu YH, Huang SH, Liu HW, Tseng FY, Wu WC*, Chang CC, Lin YH, Wu VC, Hwu CM. The role of confirmatory tests in the diagnosis of primary aldosteronism. *J Formos Med Assoc* 2024;123 Suppl 2:S104-S113. (IF: 2.6)
 55. ^{1,5}Huang JH, Lin YK, Hsieh MH, Chen SA, Chen YJ*. Ventricular response as a predictor of the termination of sustained paroxysmal atrial fibrillation. *PACE-Pacing Clin Electrophysiol* 2024; 47(6):843-852. (IF:1.7)
 56. ^{2,5}Huang KY, Chung FP, Guo CY, Chiu JH, Kuo L, Lee YC, Weng CY, Chang YY, Lin YJ, Chen CK*. Right ventricular scalloping index as cardiac magnetic resonance-derived marker for diagnosis of arrhythmogenic right ventricular cardiomyopathy. *J. Chin. Med. Assoc.* 2024; 87(5): 531-537. (IF: 1.9)
 57. ^{2,5}Huang WC, Cheng YY, Hsu CH, Wu YJ, Cheng CC, Ho WJ, Chuang HJ, Chu CY, Lin KL, Wang LY, Chiu YW, Chen KC, Chung SY, Chen YJ, Wu CH, Chen SY, Liu WS, Lin C, Chiu FC, Chen HS, Sung SH, Chou LW, Wu SH, Lin YH, Wu CY, Lin CH, Lin MC, Hung CC,

- Lei CC, Wang MT, Chen CH, Chou WLY, Hou CJY, Chen WJ*. 2023 TSOC-TACVPR-TACPAH Consensus Statement of the Rehabilitation on Patients with Pulmonary Hypertension. *Acta Cardiol Sin* 2024; 40(6):716-728. (IF: 1.8)
58. ²Huang WC, Kuramitsu S*, Kanno D, Kashima Y, Lu TM, Fujita T. Can Intravascular Lithotripsy Compress Nonruptive Calcified Nodules? *JACC-Cardiovasc Interv* 2024; 17(19): 2307-2308. (IF: 11.7)
 59. ²Huang WC, Liu FH, Cheng HM, Tsai YC, Huang YT, Lai TS, Lin YH, Wu VC, Kao HL, Hou CJY, Wu KD, Chen ST, Er LK*. Who needs to be screened for primary aldosteronism? *J. Formos. Med. Assoc.* 2024; 123: S82-S90. (IF: 2.6)
 60. ^{2,5}Huang YC, Sanotra MR, Huang CC, Hsu YJ, Liao CC*. Aerobic Exercise Modulates Proteomic Profiles in Gastrocnemius Muscle of *db/db* Mice, Ameliorating Sarcopenia. *Life-Basel* 2024; 14(3): 412. (IF:3.2)
 61. ^{2,5}Hung CL, Wu YW, Kuo L, Sung KT, Lin HH, Chang WT, Chang CH, Lai CH, Huang CY, Wang CL, Lin CC, Juang MJ, Chen PS, Wang CY, Chang HC, Chu CY, Wang WH, Tseng H, Kao YT, Wang TD, Yu WC*, Chen WJ*. 2024 Update of the TSOC Expert Consensus of Disease. *Acta Cardiol Sin* 2024; 40(5): 544-568. (IF: 1.8)
 62. ²Hung CL*, Yang N, Chiang CE. Cardiovascular Risk Stratification by LV Size Among AF Population Smaller Is Not Always Better. *J Am Coll Cardiol* 2024; 83(20): 1970-1972. (IF: 21.7)
 63. ^{1,5}Jallow AW, Nguyen DPQ, Sanotra MR, Hsu CH, Lin YF*, Lin YF. A comprehensive bibliometric analysis of global research on the role of acrolein in Alzheimer's disease pathogenesis: involvement of amyloid-beta. *Front Aging Neurosci* 2024; 16:1378260. (IF:4.1)
 64. ^{2,5}Kao YW, Chao TF, Chen SW, Cheng YW*, Chan YH, Chu PH. Initial eGFR Changes with SGLT2 Inhibitor in Patients With Type 2 Diabetes and Associations With the Risk of Abnormal Serum Potassium Level. *J Am Heart Assoc* 2024; 13(9):e033236. (IF:5.0)
 65. ^{2,5}Kao YW, Yen KC, Chen SW, Chao TF, Chan YH*. Early reduction in albuminuria is associated with a steeper 'dip' in initial estimated glomerular filtration rate but favourable long-term kidney outcomes in people with diabetes receiving sodium-glucose cotransporter-2 inhibitors. *Diabetes Obes Metab* 2024; 26(9): 3868-3879. (IF:5.4)
 66. ²Kuo L, Wang GJ, Chang SL, Lin YJ, Chung FP, Lo LW, Hu YF, Chao TF, Tuan TC, Liao JN, Chang TY, Lin CY, Liu CM, Liu SH, Kuo MR, Li GY, Huang YS, Wu C, Chen SA*, Lu CF*. Feasibility of Auto-Quantified Epicardial Adipose Tissue in Predicting Atrial Fibrillation Recurrence After Catheter Ablation. *Circ J* 2024; 88(7): 1089-1098. (IF: 3.1)
 67. ²Kuo L, Wang GJ, Su PH, Chang SL, Lin YJ, Chung FP, Lo LW, Hu YF, Lin CY, Chang TY, Chen SA*, Lu CF*. Deep learning-based workflow for automatic extraction of atria and epicardial adipose tissue on cardiac computed tomography in atrial fibrillation. *J Chin Med Assoc* 2024; 87(5):471-479. (IF:1.9)
 68. ²Kuo MJ, Lo LW*, Lin YJ, Kim S, Chen SA*. The novel automated peak frequency annotation algorithm for identifying high frequency electrogram activity following pulmonary vein isolation in atrial fibrillation ablation. *Europace* 2024; 26(6): (IF:7.9)
 69. ^{2,5}Lam SHM, Romiti GF, Olshansky B, Chao TF, Huisman MV, Lip GYH*. Combination therapy of beta-blockers and digoxin is associated with increased risk of major adverse cardiovascular events and all-cause mortality in patients with atrial fibrillation: a report from

- the GLORIA-AF registry. *Intern Emerg Med* 2024; 19(5):1369-1378. (IF:4.1)
70. ^{1,5}Lee BC, Tsai HH, Chen ZW, Chang CC, Huang JZ, Chang YY, Tsai CH, Chou CH, Liao CW, Pan CT, Wu VC, Hung CS, Tsai LK*, Lin YH*, Wu VC, Lai TS, Chueh SCJ, Yang SY, Liu KL, Chang CC, Lee BC, Wang SM, Huang KH, Lin PC, Lin YH, Hung CS, Lin LY, Liao SC, Lu CC, Chan CK, Er LK, Hu YH, Wu CH, Tsai YC, Chen ZW, Pan CT, Liao CW, Tsai CH, Chang YY, Ho CH, Huang WC, Chen YY. Aldosteronism is associated with more severe cerebral small vessel disease in hypertensive intracerebral hemorrhage. *Hypertens Res* 2024; 47(3): 608-617. (IF:4.3)
 71. ^{1,5}Lee BC, Chang CC, Kang VJW, Huang JZ, Lin YL, Chang YY, Tsai CH, Chen ZW, Liao CW, Pan CT, Wu VC, Hung CS, Chou CH*, Lin YH*, Lai TS, Chueh SCJ, Yang SY, Liu KL, Wang SM, Huang KH, Lin PC, Lin LY, Liao SC, Lu CC, Chan CK, Er LK, Hu YH, Wu CH, Tsai YC, Ho CH, Huang WC, Chen YY. Autonomous cortisol secretion promotes vascular calcification in vivo and in vitro under hyperaldosteronism. *Hypertens Res* 2024; doi: 10.1038/s41440-024-01935-w. (IF:4.300)
 72. ²Lee DY, Chang CC, Ko CF, Lee YH, Tsai YL, Chou RH, Chang TY, Guo SM*, Huang PH*. Artificial intelligence evaluation of coronary computed tomography angiography for coronary stenosis classification and diagnosis. *Eur J Clin Invest* 2024; 54(1): e14089. (IF:4.4)
 73. ²Lee DY, Chen T, Huang WC*, Chou RH, Wu CH, Yang CY*, Lee CY, Lin CC, Tarng DC. Systemic vascular resistance predicts high-output cardiac failure in patients with high-flow arteriovenous fistula. *ESC Heart Fail* 2024; 11(1): 189-197. (IF: 3.2)
 74. ²Lee DY, Huang WC*, Wu CH*, Yang CY*. Reply to: 'Non-invasively assessed hemodynamics in patients with high flow arteriovenous fistula and high output cardiac failure'. *ESC Heart Fail* 2024;11(3):1810-1811. (IF:3.2)
 75. ^{2,5}Lee KH, Yeh JT, Wu ML, Yeh WY, Lip GYH, Chiang CE, Chen CH, Cheng HM*. Oral anticoagulants and cognitive impairment in patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis. *Thromb Res* 2024; 238: 132-140. (IF: 3.7)
 76. ^{2,5}Li YH*, Wang CC, Hung CL, Wu YW, Hsu CH, Tsou YL, Wang CH, Wu CK, Lin PL, Chang HY, Sung SH, Chen ZW, Juang JMJ, Wang TD, Chen WJ. 2024 Guidelines of the Taiwan Society of Cardiology for the Diagnosis and Treatment of Heart Failure with Preserved Ejection Fraction. *Acta Cardiol Sin* 2024; 40(2): 148-171. (IF: 1.8)
 77. ^{2,5}Li YL, Leu HB, Ting CH, Lim SS, Tsai TY, Wu CH, Chung IF*, Liang KH*. Predicting long-term time to cardiovascular incidents using myocardial perfusion imaging and deep convolutional neural networks. *Sci Rep* 2024;14(1):3802. (IF: 3.8)
 78. ²Liao JN, Huang YS, Tsai CT, Kuo L, Chen SJ, Tuan TC, Chen TJ, Chen SA, Chao TF*. Gender Differences in Patients with Atrial Fibrillation Receiving Oral Anticoagulants. *Rev Cardiovasc Med* 2024; 25(3):92. (IF:1.9)
 79. ²Lin TY, Chen YY, Huang SS, Chen LW, Cheng YL, Hau WK, Hsueh CH, Chuang MJ, Huang WC*, Lu TM*. Comparison of angiography-guided vs. intra-vascular imaging-guiding percutaneous coronary intervention of acute myocardial infarction: a real world clinical practice. *Front Cardiovasc Med* 2024; 11:1421025. (IF: 2.8)
 80. ²Lin WL, Hsiao YW, Liu SH, Cheng WH, Tsai TY, Chou YH, Yang CCH, Kuo TBJ, Chen SA, Lo LW*. Effects of low-density lipoprotein cholesterol on sleep apnea: Insights from a rat

- model of cardiovascular autonomic dysregulation. *Sleep Med.* 2024; 115: 76-82. (IF: 3.8)
81. ²Lin WL, Lo LW*. Reevaluating the impact of lipid-lowering therapies on autonomic nervous system dysfunction in patients with high LDL cholesterol. *Sleep Med.* 2024; 118:115-116. (IF: 3.8)
 82. ^{2,5}Lin Y, Chao TF, Tsai ML, Tseng CJ, Wang TH, Chang CH, Lin YS, Yang N, Chu PH, Hung MJ, Wu VCC*, Chen TH*. Cardiovascular and renal outcomes in patients with atrial fibrillation and stage 4-5 chronic kidney disease receiving direct oral anticoagulants: a multicenter retrospective cohort study. *J Thromb Thrombolysis* 2024; 57(1): 89-100. (IF: 2.3)
 83. ^{2,5}Liou YJ, Chen MH, Hsu JW, Huang KL, Huang PH*, Bai YM*. Dysfunction of circulating endothelial progenitor cells in major depressive disorder. *Acta Neuropsychiatr* 2024; 36(3):153-161. (IF:2.6)
 84. ²Liu CM*, Chen WS, Chang SL, Hsieh YC, Hsu YH, Chang HX, Lin YJ, Lo LW, Hu YF, Chung FP, Chao TF, Tuan TC, Liao JN, Lin CY, Chang TY, Kuo L, Wu C, Wu MH, Chen CK, Chang YY, Shiu YC, Lu HHS*, Chen SA. Use of artificial intelligence and I-Score for prediction of recurrence before catheter ablation of atrial fibrillation. *Int J Cardiol* 2024; 402: 131851. (IF:3.2)
 85. ²Liu CM, Lin FJ, Chhay C, Chen YC, Lin YK, Lu YY, Chan CS, Higa S, Chen SA, Chen YJ. Ibrutinib, a Bruton's tyrosine kinase inhibitor, regulates ventricular electromechanical activities and enhances arrhythmogenesis. *Eur J Pharmacol* 2024; 977: 176675. (IF: 4.2)
 86. ^{2,5}Liu KI, Hung MH, Huang CC*, Chen JW. Cumulative blood pressure load and hypertensive nephropathy in Han Chinese hypertensive patients. *J Clin Hypertens* 2024; 26(2): 207-216. (IF: 2.7)
 87. ^{2,5}Liu Y, Chen Y, Lam SHM, Huang B, Romiti GF, Alam U, Chao TF, Olshansky B, Hong K, Huisman MV, Lip GYH*. Diabetes mellitus and adverse clinical events in patients with atrial fibrillation: A report from the GLORIA-AF registry phase III. *Diabetes Obes Metab* 2024; 26(12):5795-5804. (IF:5.4)
 88. ^{2,5}Lu YW, Chang CC*, Chou RH, Lee WJ, Chen LK, Huang PH*, Lin SJ. Sex differences in the frailty phenotype and mortality in the I-Lan longitudinal aging study cohort. Sex differences in the frailty phenotype and mortality in the I-Lan longitudinal aging study cohort. *BMC Geriatr* 2024; 24(1):182. (IF: 3.4)
 89. ^{2,5}Mei DA, Romiti GF*, Bucci T, Corica B, Imberti JF, Bonini N, Vitolo M, Shantsila A, Tse HF, Chao TF, Boriani G, Proietti M, Lip GYH. Peripheral artery disease, antithrombotic treatment and outcomes in European and Asian patients with atrial fibrillation: analysis from two prospective observational registries. *BMC Med* 2024; 22(1):567. (IF:7.1)
 90. ^{2,5}Mentz RJ, Stebbins A, Butler J, Chiang CE, Ezekowitz JA, Hernandez AF, Hilkert R, Lam CSP, McDonald K, O'Connor CM, Pieske B, Ponikowski P, Roessig L, Sweitzer NK, Voors AA, Anstrom KJ, Armstrong PW*. Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction. *JACC-Heart Fail* 2024; 12(5): 839-846. (IF: 10.3)
 91. ^{2,5}Nagai M*, Dote K, Park S, Turana Y, Buranakitjaroen P, Cheng HM, Soenarta AA, Li Y, Kario K. Obstructive sleep apnea and non-dipper: epiphenomena or risks of Alzheimer's disease? A review from the HOPE Asia Network. *Hypertens Res* 2024; 47(2): 271-280. (IF: 4.3)

92. ^{2,5}Nguyen DSN, Lin CY*, Chung FP, Chang TY, Lo LW, Lin YJ, Chang SL, Hu YF, Tuan TC, Chao TF, Liao JN, Kuo L, Liu CM, Liu SH, Wu C, Kuo MJ, Li GY, Huang YS, Wu SJ, Siow YK, Bautista JAL, Cao DT, Chen SA. Signal-averaged electrocardiography as a noninvasive tool for evaluating the ventricular substrate in patients with nonischemic cardiomyopathy: reassessment of an old tool. *Front Cardiovasc Med* 2024; 11:1306055. (IF: 2.8)
93. ^{1,5}Rai V*, Iglesias JF, Bossard M, Dahal K, Chang CC, Tomaniak M. Editorial: Reviews in bioresorbable scaffold. *Front Cardiovasc Med* 2024; 11:1437555. (IF:2.8)
94. ^{2,5}Romiti GF, Corica B, Mei DA, Bisson A, Boriani G, Olshansky B, Chao TF, Huisman MV, Proietti M, Lip GYH*. Patterns of comorbidities in patients with atrial fibrillation and impact on management and long-term prognosis: an analysis from the Prospective Global GLORIA-AF Registry. *BMC Med* 2024; 22(1):151. (IF:7.1)
95. ^{2,5}Siow YK, Lin CY*, Chung FP, Lin YJ, Chang SL, Lo LW, Hu YF, Liao JN, Chang TY, Tuan TC, Kuo L, Wu C, Liu CM, Liu SH, Li GY, Kuo MJ, Wu SJ, Bautista JA, Huang YS, Nguyen DSN, Chen SA. Catheter ablation in patients with atrial fibrillation and dilated cardiomyopathy. *Front Cardiovasc Med* 2024; 11:1305485. (IF:2.8)
96. ^{2,5}Solomon SD*, McMurray JJV*, Vaduganathan M, Claggett B, Jhund PS, Desai AS, Henderson AD, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Abidin IZ, Alcocer-Gamba MA, Atherton JJ, Bauersachs J, Chang-Sheng M, Chiang CE, Chioncel O, Chopra V, Comin-Colet J, Filippatos G, Fonseca C, Gajos G, Goland S, Goncalvesova E, Kang SK, Katova T, Kosiborod MN, Latkovskis G, Lee APW, Linssen GCM, Llamas-Esperon G, Mareev V, Martinez FA, Melenovsky V, Merkely B, Nodari S, Petrie MC, Saldarriaga CI, Saraiva JFK, Sato N, Schou M, Sharma K, Troughton R, Udell JA, Ukkonen H, Vardeny O, Verma S, von Lewinski D, Voronkov L, Yilmaz MB, Zieroth S, Lay-Flurrie J, van Gameren I, Amarante F, Kolkhof P, Viswanathan P. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. *N Engl J Med* 2024; 391(16):e35. (IF:96.3)
97. ^{1,5}Solomon SD*, Ostrominski JW, Vaduganathan M, Claggett B, Jhund PS, Desai AS, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad, F Abidin IZ, Alcocer-Gamba MA, Atherton JJ, Bauersachs J, Ma CS, Chiang, CE, Chioncel O, Chopra V, Comin-Colet J, Filippatos G, Fonseca C, Gajos G, Goland S, Goncalvesova E, Kang SM, Katova T, Kosiborod MN, Latkovskis G, Lee APW, Linssen GCM, Llamas-Esperon G, Mareev V, Martinez FA, Melenovsky V, Merkely B, Nodari S, Petrie MC, Saldarriaga CI, Saraiva JFK, Sato N, Schou M, Sharma K, Troughton R, Udell JA, Ukkonen H, Vardeny O, Verma S, von Lewinski D, Voronkov LG, Yilmaz MB, Zieroth S, Lay-Flurrie J, van Gameren I, Amarante F, Viswanathan P, McMurray JJV. Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FIN EARTS-HF trial. *Eur J Heart Fail* 2024; 26(6): 1334-1346. (IF: 16.9)
98. ²Sung WT, Chuang MJ, Tsai YL, Chou RH, Chang CC*, Huang PH*. Impacts of the SYNTAX score I, II and SYNTAX score II 2020 on left main revascularization. *Sci Rep* 2024; 14(1):1073. (IF: 3.8)
99. ^{2,5}Tsai CT, Chan YH, Liao JN, Chen TJ, Lip GYH, Chen SA, Chao TF*. Risk of Incident Atrial Fibrillation and Subsequent Use of Oral Anticoagulants in Patients with Dementia. *Thromb Haemost* 2024; 124(03): 253-262. (IF: 5.0)
100. ²Tsai CT, Chan YH, Liao JN, Chen TJ, Lip GYH, Chen SA, Chao TF*. The optimal antithrombotic strategy for post-stroke patients with atrial fibrillation and extracranial artery

- stenosis-a nationwide cohort study. *BMC Med* 2024; 22(1): (IF:7.1)
101. ^{2,5}Tsai MT, Lin YS, Huang SS, Weng SC, Yang CY, Lee KH, Ou SM, Lin YP, Huang CC, Tseng WC*, Tarng DC*. Physical activity modifies cognitive impairment-associated mortality risks among chronic kidney disease. *J Affect Disord* 2024; 366:354-363. (IF: 4.9)
 102. ²Tseng CH, Hu YA, Chen YT, Yu WC, Lin CC, Li SY*. Beyond prevalence: significance and differential impact of echocardiographic abnormalities in dialysis patients. *J Nephrol* 2024; 37(5):1261-1271. (IF:2.7)
 103. ^{1,5}Tzeis S*, Gerstenfeld EP, Kalman J, Saad EB, Shamloo AS, Andrade JG, Barbhaiya CR, Baykaner T, Boveda S, Calkins H, Chan NY, Chen ML, Chen SA, Dagues N, Damiano RJ, De Potter T, Deisenhofer I, Derval N, Di Biase L, Duytschaever M, Dyrda K, Hindricks G, Hocini M, Kim YH, la Meir M, Merino JL, Michaud GF, Natale A, Nault I, Nava S, Nitta T, O'Neill M, Pak HN, Piccini JP, Purerfellner H, Reichlin T, Saenz LC, Sanders P, Schilling R, Schmidt B, Supple GE, Thomas KL, Tondo C, Verma A, Wan EY. 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation. *Europace* 2024; 26(4):euae043. (IF:7.9)
 104. ^{1,5}Tzeis S*, Gerstenfeld EP, Kalman J, Saad, EShamloo AS, Andrade JG, Barbhaiya CR, Baykaner T, Boveda S, Calkins H, Chan NY, Chen ML, Chen SA, Dagues N, Damiano RJ, De Potter T, Deisenhofer I, Derval N, Di Biase L, Duytschaever M, Dyrda K, Hindricks G, Hocini M, Kim YH, la Meir M, Merino JL, Michaud GF, Natale A, Nault I, Nava S, Nitta T, O'Neill M, Pak HN, Piccini JP, Puererfellner H, Reichlin T, Saenz LC, Sanders P, Schilling R, Schmidt B, Supple GE, Thomas KL, Tondo C, Verma A, Wan EY. 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation. *J Interv Card Electrophysiol* 2024; 67(5): 921-1072. (IF: 2.1)
 105. ²Wang WT, Wu TH, Er LK, Huang CW, Tu KH, Fan KC, Tsai CH, Wang SY, Wu CY, Huang SH, Liu HW, Tseng FY, Wu WC, Chang CC, Cheng HM*, Lin LY, Chueh JS, Lin YH, Hwu CM*, Wu VC*. Recent progress in unraveling cardiovascular complications associated with primary aldosteronism: a succinct review. *Hypertens Res* 2024; 47(5): 1103-1119. (IF: 4.3)
 106. ^{2,5}Wang YH, Lu YW, Chan SW*, Kuo L*, Chen SA. The application of cardiac magnetic resonance imaging (CMR) in myocarditis after COVID-19 vaccines : Case series from single medical center in Taiwan. *J Chin Med Assoc* 2024; 151-155. (IF:1.9)
 107. ²Weng CJ, Li CH, Lin YJ, Chang SL, Hu YF, Chung FP, Liao JN, Tuan TC, Chao TF, Lin CY, Chang TY, Liu CM, Liu SH, Chen WT, Chang WH, Chuong NKT, Kuo MR, Kao PH, Li GY, Ahliah I, Chen SA*, Lo LW*. Skin sympathetic nerve activity in different ablation settings for atrial fi brillation. *J Cardiol* 2024; 83(5): 306-312. (IF: 2.5)
 108. ^{2,5}Wong CX, Tse HF, Choi EK, Chao TF, Inoue K, Poppe K, Tan E, Yuniadi Y, Fadreguilan E, Johar S, Chan NY, Namboodiri N, Hossain SM, He H, Chantrarat T, Bin Abd Ghani AR, Davaakhuu N, Nwe N, Irfan G, Ton MT, Gunawardena R, Sanders P*. The burden of atrial fibrillation in the Asia-Pacific region. *Nat Rev Cardiol* 2024; 21(12):841-843. (IF:41.7)
 109. ²Wu CI, Chen IC, Chen YY, Chen YM, Lin YJ, Hsieh YC, Chen SA*. Susceptibility of atrial fibrillation in genetic architecture and heritability: A genome-wide association study in Taiwan. *Heart Rhythm* 2024; 21(9): 1656-1657. (IF: 5.6)
 110. ^{2,5}Yang MM, Kondo T, Jhund PS, Alcocer-Gamba MA, Borleffs CJW, Chiang CE, Comin-

- Colet J, Desai AS, Dobreanu D, Drozd J, Han YL, Janssens SP, Katova T, Kosiborod MN, Lam CSP, Merkely B, Pham VN, Thierer J, Vaduganathan M, Verma S, Solomon SD, Mcurray JJV*. Geographical variation in patient characteristics and outcomes in heart failure with mildly reduced and preserved ejection fraction. *Eur J Heart Fail* 2024; 26(8):1788-1803. (IF:16.9)
111. ^{2,5}Yang YH, Chang YL, Lee BC, Lu CC, Wang WT, Hu YH, Liu HW, Lin YH, Chang CC*, Wu WC, Tseng FY, Lin YH, Wu VC, Hwu CM. Strategies for subtyping primary aldosteronism. *J Formos Med Assoc* 2024; 123 Suppl 2:S114-S124. (IF: 2.6)
 112. ^{2,5}Yeh JT, Huang CC*, Leu HB, Yin WH, Tseng WK, Wu YW, Lin TH, Yeh H, Chang KC, Wang JH, Wu CC, Chen JW. Fatty acid-binding protein-3 and renal function decline in patients with chronic coronary syndrome. *Clin Cardiol* 2024; 47(1):e24210. (IF:2.4)
 113. ^{2,5}Yu TH, Lee TL, Hsuan CF, Wu CC, Wang CP, Lu YC, Wei CT, Chung FM, Lee YJ, Tsai IT*, Tang WH. Inter-relationships of risk factors and pathways associated with all-cause mortality in patients with chronic schizophrenia. *Front Psychiatry* 2024; 14:1309822. (IF:3.2)

Endocrinology and Metabolism

1. ^{2,5}Chang LH, Chang TT, Chu CH, Huang CC, Lin LY*. Soluble tumor necrosis factor receptor type 1 is an alternative marker of urinary albumin-creatinine ratio and estimated glomerular filtration rate for predicting the decline of renal function in subjects with type 2 diabetes mellitus. *Clin Chim Acta* 2024;558:117880. (IF: 3.2)
2. ^{2,5}Chang TT*, Li YZ, Mo HW, Chen C, Lin LY, Chang CC, Chen JW. Inhibition of CCL7 improves endothelial dysfunction and vasculopathy in mouse models of diabetes mellitus. *Sci Transl Med* 2024;16(763):eadn1507. (IF: 15.8)
3. ^{2,5}Chang TT*, Lin LY, Chen C, Chen JW*. CCL4 contributes to aging related angiogenic insufficiency through activating oxidative stress and endothelial inflammation. *Angiogenesis* 2024;27(3):475-499. (IF: 9.2)
4. ^{2,5}Chen C, Lin LY, Wu YW, Chen JW, Chang TT*. CXCL5 inhibition improves kidney function by protecting renal tubular epithelial cells in diabetic kidney disease. *Clin Immunol* 2024;268:110369. (IF: 4.5)
5. ^{2,5}Chen CE, Guo JY, Chou RH*, Wu CH, Kuo CS, Wei JH, Huang PH*. Circulating corin concentration is associated with risk of mortality and acute kidney injury in critically ill patients. *Sci Rep* 2024;14(1):19848. (IF: 3.8)
6. ^{2,5}Chen KL, Chou RH*, Chang CC, Kuo CS, Wei JH, Huang PH*, Lin SJ. The high-density lipoprotein cholesterol (HDL-C)-concentration-dependent association between anti-inflammatory capacity and sepsis: A single-center cross-sectional study. *PLoS One* 2024;19(4):e0296863. (IF: 2.9)
7. ^{2,5}Chen YY, Huang SC, Pan CT, Peng KY, Lin LY, Chan CK*, Shun CT. The predictors of long-term outcomes after targeted therapy for primary Aldosteronism. *J Formos Med Assoc* 2024;123():S135-S140. (IF: 2.6)
8. ²Cheng WY, Chang LH, Chen HS*. The effect of statin treatment on glucose homeostasis in prediabetic individuals: A prospective randomized controlled trial. *J Chin Med Assoc* 2024;87(7):664-669. (IF: 1.9)

9. ^{2,5}Cheng YF, Wang CC*, Tsai PS, Lin DC, Huang WH. Langerhans cell histiocytosis of the thyroid mimicking thyroiditis in a boy: a case report and literature review. *BMC Pediatr* 2024;24(1):66. (IF: 2.0)
10. ^{2,5}Cheng YS, Lin CP, Chen LYA, Hwang WR, Lin YC, Chen YC*. Short-Term Effects of an eHealth Care Experiential Learning Program Among Patients With Type 2 Diabetes: Randomized Controlled Trial. *J Med Internet Res* 2024;26:e53509. (IF: 5.8)
11. ^{1,5}Chiu LT, Lin YL, Wang CH, Hwu CM, Liou HH*, Hsu BG*. Electrochemical Skin Conductance by Sudoscan in Non-Dialysis Chronic Kidney Disease Patients. *J Clin Med* 2024;13(1):187. (IF: 3.0)
12. ^{1,5}Hawkes G*, Beaumont RN, Li ZL, Mandla R, Li XH, Albert CM, Arnett DK, Ashley-Koch AE, Ashrani AA, Barnes KC, Boerwinkle E, Brody JA, Carson AP, Chami N, Chen YDI, Chung MK, Curran JE, Darbar D, Ellinor PT, Fornage M, Gordeuk VR, Guo XQ, He J, Hwu CM, Kalyani RR, Kaplan R, Kardia SLR, Kooperberg C, Loos RJF, Lubitz SA, Minster RL, Naseri T, Viali S, Mitchell BD, Murabito JM, Palmer ND, Psaty BM, Redline S, Shoemaker MB, Silverman EK, Telen MJ, Weiss ST, Yanek LR, Zhou HF, Liu CT, North KE, Justice AE, Locke JM, Owens N, Murray A, Patel K, Frayling TM, Wright CF, Wood AR, Lin XH, Manning A, Weedon MN*. Whole-genome sequencing in 333,100 individuals reveals rare non-coding single variant and aggregate associations with height. *Nat Commun* 2024;15(1):8549. (IF: 14.7)
13. ^{1,5}Hsiao YC, Lee TL, Lin FJ, Hsuan CF, Yeh CF, Chang WT, Kao HL, Jeng JS, Wu YW, Hsieh IC, Fang CC, Wang KY, Chang KC, Lin TH, Sheu WHH, Li YH, Yin WH, Yeh H, Chen JW, Wu CC*. A risk stratification model modified from the U.S. guideline could be applied in an Asian population with or without ASCVD: Validation study. *Biomed J* 2024;47(3):100653. (IF: 4.1)
14. ^{2,5}Hu YS, Wu CA, Lin DC, Lin PW, Lee HJ, Lin LY, Lin CJ*. Applying ONCO-RADS to whole-body MRI cancer screening in a retrospective cohort of asymptomatic individuals. *Cancer Imaging* 2024;24(1):22. (IF: 3.5)
15. ^{2,5}Huang CC, Yeh HY, Lin R, Liao TL, Shen HC, Yang YY*, Lin HC. Inhibition of visceral adipose tissue-derived pathogenic signals by activation of adenosine A_{2A}R improves hepatic and cardiac dysfunction of NASH mice. *Am J Physiol-Gastroint Liver Physiol* 2024;326(4):G385-G397. (IF: 3.9)
16. ²Huang CJ, Li JZ, Hwu CM, Chen HS, Yeh CC, Wang FF*, Yang CC*. Determination of the Elemental Iodine in Human Breast Milk by Inductively Coupled Plasma mass Spectrometry. *Biol Trace Elem Res* 2024;202(4):1517-1523. (IF: 3.4)
17. ^{1,5}Huang CW, Tu KH, Fan KC, Tsai CH, Wang WT, Wang SY, Wu CY, Hu YH, Huang SH, Liu HW, Tseng FY, Wu WC*, Chang CC, Lin YH, Wu VC, Hwu CM. The role of confirmatory tests in the diagnosis of primary aldosteronism. *J Formos Med Assoc* 2024;123():S104-S113. (IF: 2.6)
18. ^{2,5}Huang JF, Chang TJ, Yeh ML, Shen FC, Tai CM, Chen JF, Huang YH, Hsu CY, Cheng PN, Lin CL, Hung CH, Chen CC, Lee MH, Lee CC, Lin CW, Liu SC, Yang H, Chien RN, Kuo CS, Peng CY, Chang ML, Huang CF, Yang YS, Yang HC, Lin HC, Ou HY, Liu CJ, Tseng CH, Kao JH, Chuang WL, Huang CN, Chen PJ, Wang CY*, Yu ML*. Clinical care guidance in patients with diabetes and metabolic dysfunction-associated steatotic liver disease: A joint consensus. *Hepatol Commun* 2024;8(11):e0571. (IF: 5.6)

19. ²Ko FS, Yeh YK, Yen FS*, Hwu CM*. Deciphering the causal tapestry between cardiorespiratory fitness and type 2 diabetes mellitus. *J Diabetes Investig* 2024;15(4):426-428. (IF: 3.1)
20. ²Kuo CS, Chen HS*. β -cell function and long-term glycemic control in patients newly diagnosed with type 2 diabetes with moderate hyperglycemia after a 6-month course of basal insulin therapy. *Diabetes Res Clin Pract* 2024;215:111814. (IF: 6.1)
21. ²Kuo CS, Kuo NR, Yeh YK, Lee YJ, Chuang LM, Chen HF, Chen CC, Lee CC, Hsu CC, Li HY, Ou HY*, Hwu CM*. Residual risk of cardiovascular complications in statin-using patients with type 2 diabetes: the Taiwan Diabetes Registry Study. *Lipids Health Dis* 2024;23(1):24. (IF: 3.9)
22. ^{2,5}Lai HF, Hang JF, Kuo PC, Kuo CS, Yao SF, Chen JY*, Lee CH. *BRAF V600E* Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma. *Ann Surg Oncol* 2024;31(5):3495-3501. (IF: 3.4)
23. ²Lee PS, Chen JY, Pan LH, Hwu CM, Hang JF, Kuo CS*. Unveiling a rare BRAF mutation in minimally invasive follicular thyroid carcinoma: A case report. *Medicine (Baltimore)* 2024;103(34):e39364. (IF: 1.4)
24. ^{2,5}Lin YH, Chang HT*, Wang YF, Fuh JL, Wang SJ, Chen HS, Li SR, Lin MH, Chen TJ, Hwang SJ. The association of the comorbidity status of metabolic syndrome and cognitive dysfunction with health-related quality of life. *Qual Life Res* 2024;33(12):3421-3433. (IF: 3.3)
25. ^{1,5}Malik RA*, Hwu CM, Jammah AA, Arteaga-Diaz JM, Djaballah K, Pilorget V, Alvarez A, Vera C, Vikulova O. Real-world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international multicentre 12-month prospective observational study. *Diabetes Obes Metab* 2024;26(7):2811-2819. (IF: 5.4)
26. ²Pan LH, Chen YY, Pan CT, Hsu CY, Tseng CS, Yen IW, Chan CK, Lin LY*. Follow-up care and assessment of comorbidities and complications in patients with primary aldosteronism: The clinical practice guideline of the Taiwan Society of aldosteronism. *J Formos Med Assoc* 2024;123():S141-S152. (IF: 2.6)
27. ^{1,5}Shen FC, Chu CH, Chen JF, Kuo CS, Hsu CY, Lin CH, Sheen YJ, Su SC, Tien KJ, Lu CH, Lee CC, Yang YS, Tu ST, Chen PT, Chen CC, Chien MN, Li HY, Sheu WHH, Huang CN*, Wang CY*, Ou HY*. Optimizing lipid control in Taiwanese diabetic patients: A collaborative consensus by the Diabetes Association of the Republic of China (Taiwan) and the Taiwanese Association of Diabetes Educators. *J Diabetes Investig* 2024;15(8):1151-1160. (IF: 3.1)
28. ^{2,5}Shen HC, Pan MH, Huang CJ, Yeh HY, Yang H, Lin YH, Huang CC, Lee KC, Yang YY*, Hou MC. Multiple genetic polymorphisms are associated with the risk of metabolic syndrome fatty liver and airflow limitation: A Taiwan Biobank study. *Gene* 2024;927:148660. (IF: 2.6)
29. ¹Sheu WHH*. Birthweight and risk of diabetes in later life. *J Diabetes Investig* 2024;15(5):557-558. (IF: 3.1)
30. ^{1,5}Smith JL, Tcheandjieu C, Dikilitas O, Iyer K, Miyazawa K, Hilliard A, Lynch J, Rotter JI, Chen YDI, Sheu WHH, Chang KM, Kanoni S, Tsao PS, Ito K, Kosel M, Clarke SL, Schaid DJ, Assimes TL, Kullo IJ*. Multi-Ancestry Polygenic Risk Score for Coronary Heart Disease Based on an Ancestrally Diverse Genome-Wide Association Study and Population-Specific Optimization. *Circ-Genom Precis Med* 2024;17(3):e004272. (IF: 6.0)
31. ²Su GY, Yeh CC, Yang SJ, Yang CC, Hwu CM, Wang FF, Huang CJ*. Assessment of iodine

- nutritional status and gestational thyroid function reference ranges during the first trimester of pregnancy in Taiwan. *J Chin Med Assoc* 2024;87(6):590-596. (IF: 1.9)
32. ^{2,5}Suzuki K, Hatzikotoulas K*, ..., Hwu CM, ..., Sheu WHH, ..., etc. Genetic drivers of heterogeneity in type 2 diabetes pathophysiology. *Nature* 2024;627(8003):347-357. (IF: 50.5)
 33. ^{2,5}Wei SY, Liu YP, Lin DC, Tsai PS*. Klippel-Trenaunay syndrome with profound abdominal lymphatic-venous malformation in a three-day-old newborn: a case report and literature review. *Front Pediatr* 2024;12:1326909. (IF: 2.1)
 34. ^{2,5}Yang JH, Lin WL, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, Huang SC, Cheng HH, Yang YW, Lin YZ, Hsu HM, Lin CJ, Teng HW*. The survival outcome differs between left-sided colon cancer and middle/low rectal cancer after colorectal hepatic metastasectomy. *J Gastrointest Surg* 2024;28(8):1250-1258. (IF: 2.2)
 35. ^{2,5}Yang YH, Chang YL, Lee BC, Lu CC, Wang WT, Hu YH, Liu HW, Lin YH, Chang CC*, Wu WC, Tseng FY, Lin YH, Wu VC, Hwu CM. Strategies for subtyping primary aldosteronism. *J Formos Med Assoc* 2024;123():S114-S124. (IF: 2.6)
 36. ²Yeh YK, Lin KH, Sheu WHH, Lo SH, Yeh YP, Huang CN, Hwu CM*, Lu CH*. Determinants of early chronic kidney disease in patients with recently diagnosed type 2 diabetes mellitus: a retrospective study from the Taiwan Diabetes Registry. *BMC Nephrol* 2024;25(1):133. (IF: 2.2)
 37. ²Yeh YK, Yen FS, Wei JCC, Hu KC, Yu TS, Hsu CC*, Hwu CM*. Metformin and the risks of cellulitis foot infections and amputation in patients with type 2 diabetes. *J Chin Med Assoc* 2024;87(4):384-392. (IF: 1.9)
 38. ^{2,5}Yen FS, Hou MC, Wei JCC, Shih YH, Hsu CY, Hsu CC*, Hwu CM*. Glucagon-like Peptide-1 Receptor Agonist Use in Patients With Liver Cirrhosis and Type 2 Diabetes. *Clin Gastroenterol Hepatol* 2024;22(6):1255-1264. (IF: 11.6)
 39. ^{2,5}Yen FS, Hou MC, Wei JCC, Shih YH, Hwu CM*, Hsu CC*. Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes. *BMC Med* 2024;22(1):8. (IF: 7.1)
 40. ^{2,5}Yen FS, Hwu CM, Liu JS, Wu YL, Chong K, Hsu CC*. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients With Stage 5 Chronic Kidney Disease. *Ann Intern Med* 2024;177(6):693-700. (IF: 19.6)
 41. ^{2,5}Yen FS, Wang SI, Hsu CC, Hwu CM*, Wei JCC*. Sodium-Glucose Cotransporter-2 Inhibitors and Nephritis Among Patients With Systemic Lupus Erythematosus. *JAMA Netw Open* 2024;7(6):e2416578. (IF: 10.5)
 42. ^{2,5}Yen FS, Wei JCC, Wu YL, Lo YR, Chen CM, Hwu CM, Hsu CC*. Impact of family income on the development of gestational diabetes mellitus and the associated birth outcomes: A nationwide study. *J Diabetes Investig* 2024;16(1):51-59. (IF: 3.1)
 43. ^{2,5}Yen FS*, Hwu CM, Hsu CC. A Reply. *Clin Gastroenterol Hepatol* 2024;22(4):902-903. (IF: 11.6)
 44. ^{2,5}Yen YH, Yen FS, Ko FS, Wei JCC, Huang YH, Yu TS, Hwu CM*, Hsu CC*. Microvascular disease and its association with dementia in patients with type 2 diabetes: A nationwide cohort study in Taiwan. *Diabetes Obes Metab* 2024;26(11):5399-5407. (IF: 5.4)
 45. ^{2,5}Ying TH, Huang CJ, Hsieh CJ, Wu PJ, Yeh CC, Hung PK, Chang WH, Wu MH, Hung H,

- Chang JW, Wang CT, Arcega RD, Mahmudiono T, Lee CC, Chen HL*. Potential Factors Associated with the Blood Metal Concentrations of Reproductive-Age Women in Taiwan. *Expo Health* 2024;16(1):71-86. (IF: 4.6)
46. ^{2,5}Ying TH, Huang CJ, Hsieh CJ, Wu PJ, Yeh CC, Hung PK, Chang WH, Wu MH, Hung H, Chang JW, Wang CT, Arcega RD, Mahmudiono T, Lee CC, Chen HL*. Potential Factors Associated with the Blood Metal Concentrations of Reproductive-Age Women in Taiwan (Mar 10.1007/s12403-023-00541-4 2023). *Expo Health* 2024;16(2):617-617. (IF: 4.6)
 47. ^{2,5}Ying TH, Huang CJ, Hsieh CJ, Wu PJ, Yeh CC, Hung PK, Chang WH, Wu MH, Hung H, Chang JW, Wang CT, Arcega RD, Mahmudiono T, Lee CC, Chen HL*. Potential Factors Associated with the Blood Metal Concentrations of Reproductive-Age Women in Taiwan (vol 16 pg 71 2024). *Expo Health* 2024;16(5):1291-1291. (IF: 4.6)

Infectious Diseases

1. ^{2,4}Chang MC, Wu PF, Ho YC, Lin WY, Wu CY, Liu SY, Liu CJ*, Lin YT*. Clinical outcomes and safety of remdesivir in hospitalized individuals with COVID-19 with or without severe renal impairment. *J Infect Public Health* 2024;17(7):102460. (IF: 4.7)
2. ^{2,5}Chen RZ, Lu PL, Yang TY, Lin SY, Tang HJ, Chang FY, Yang YS, Chiang TT, Wang FD, Wu TS, Shie SS, Ho MW, Liu JW, Shi ZY, Chou CH*, Chuang YC. Efficacy of cefoperazone/sulbactam for ESBL-producing *Escherichia coli* and *Klebsiella pneumoniae* bacteraemia and the factors associated with poor outcomes. *J Antimicrob Chemother* 2024;79(3):648-655. (IF: 3.9)
3. ²Chou SH, Chuang C, Juan CH, Ho YC, Liu SY, Chen L, Lin YT*. Mechanisms and fitness of ceftazidime/avibactam-resistant *Klebsiella pneumoniae* clinical strains in Taiwan. *Int J Antimicrob Agents* 2024;64(2):107244. (IF: 4.9)
4. ^{2,5}Hsu PC, Lin YT, Kao KC, Peng CK, Sheu CC, Liang SJ, Chan MC, Wang HC, Chen YM, Chen WC, Yang KY*. Risk factors for prolonged mechanical ventilation in critically ill patients with influenza-related acute respiratory distress syndrome. *Respir Res* 2024;25(1):9. (IF: 4.7)
5. ^{2,5}Hu EW, Lu HF, Lin YT, Yang TC, Li LH*. Modulatory role of SmeQ in SmeYZ efflux pump-involved functions in *Stenotrophomonas maltophilia*. *J Antimicrob Chemother* 2024;79(2):383-390. (IF: 3.9)
6. ^{2,4}Huang JP, Yeh CM, Gong YW, Tsai MH, Lin YT, Tsai CK*, Liu CJ*. Risk and impact of cytomegalovirus infection in lymphoma patients treated with bendamustine. *Ann Hematol* 2024;103(10):4099-4109. (IF: 3.0)
7. ^{1,5}Lee KH, Jiamsakul A, Kiertiburanakul S, Borse R, Khol V, Yuniastuti E, Azwa I, Somia IKA, Chaiwarith R, Pham TN, Khusuwan S, Do CD, Kumarasamy N, Gani Y, Ditangco R, Ng OT, Pujari S, Lee MP, Avihingsanon A, Chen HP, Zhang FJ, Tanuma J, Ross J, Choi JY*. Risk factors for toxoplasmosis in people living with HIV in the Asia-Pacific region. *PLoS One* 2024;19(7):e0306245. (IF: 2.9)
8. ^{2,5}Lee YL, Hsieh SM, Lin YT, Shie SS, Yang CJ, Hsueh PR*. Burden of respiratory syncytial virus in older adults in Taiwan: An expert perspective on knowledge gaps. *J Microbiol Immunol Infect* 2024;57(4):523-532. (IF: 4.5)

9. ^{2,5}Liao CH, Lu HF, Yang CW, Yeh TY, Lin YT, Yang TC*. HemU and TonB1 contribute to hemin acquisition in *Stenotrophomonas maltophilia*. *Front Cell Infect Microbiol* 2024;14:1380976. (IF: 4.6)
10. ^{2,4}Liao JN, Huang YS, Tsai CT, Kuo L, Chen SJ, Tuan TC, Chen TJ, Chen SA, Chao TF*. Gender Differences in Patients with Atrial Fibrillation Receiving Oral Anticoagulants. *Rev Cardiovasc Med* 2024;25(3):92. (IF: 1.9)
11. ^{2,5}Lin KY, Wang CH, Su LY, Lin IF, Liu CW, Wu PF, Tsai WC, Chang CN, Hung MC, Huang CH, Chiu NC, Cheng MF, Hsieh SM, Wang NC, Wang HW, Wong SS, Lin PC, Tsai MH, Yang SC, Lin HC, Lee SSJ*, Chen YC*, Wang FD. Recommendations and guidance for herpes zoster vaccination for adults in Taiwan. *J Microbiol Immunol Infect* 2024;57(5):669-684. (IF: 4.5)
12. ²Lin YT*, Chuang C, Chou SH, Juan CH, Yang TC, Kreiswirth BN, Chen L*. Emergence of OXA-48-producing hypervirulent *Klebsiella pneumoniae* strains in Taiwan. *Eur J Clin Microbiol Infect Dis* 2024;43(2):389-393. (IF: 3.7)

Nephrology

1. ^{2,5}Chang TT*, Li SY, Tsai MT, Chiang CH, Chen C, Chen JW. CXCL5 inhibition ameliorates acute kidney injury and prevents the progression from acute kidney injury to chronic disease. *Clin Sci* 2024;138(22):1451-1466. (IF: 6.7)
2. ^{2,5}Chang YP, Lin CC, Wu JH, Hsieh YH, Chou KH, Su CT*. The impact of photobiomodulation on sleep and life quality in hemodialysis patients: A randomized controlled trial. *Lasers Med Sci* 2024;39(1):169. (IF: 2.1)
3. ²Chen FY, Li SE, Tsai JE, Lu PY, Li YH, Tan AC, Li SY, Chuang YF, Chen CM*, Lin CC*. The impact of the COVID-19 pandemic on dyslipidemia in peritoneal dialysis patients. *J Chin Med Assoc* 2024;87(12):1039-1046. (IF: 1.9)
4. ^{2,5}Chen YT, Lin CC, Huang PH*, Li SY*. Comparative analysis of hemodialysis and peritoneal dialysis on the risk of new onset diabetes mellitus. *J Formos Med Assoc* 2024;123(5):606-612. (IF: 2.6)
5. ^{2,5}Chou RH, Hsu BWY, Yu CL, Chen TY, Ou SM, Lee KH, Tseng VS*, Huang PH*, Tarng DC*. Machine-learning models are superior to severity scoring systems for the prediction of the mortality of critically ill patients in a tertiary medical center. *J Chin Med Assoc* 2024;87(4):369-376. (IF: 1.9)
6. ^{2,5}Chou YL, Chen HL, Hsu BG, Yang CY, Chen CH, Lee YC, Tsai IL, Sung CC, Wu CC, Yang SR, Suzuki Y, Yates E, Hua KF, Yu LG, Liu FT, Chen A, Ka SM*. Galectin-3 contributes to pathogenesis of IgA nephropathy. *Kidney Int* 2024;106(4): 658-670. (IF: 14.8)
7. ^{2,5}Hsiao FY, Tan EC, Meng LC, Lin YC, Chen HM, Guan ST, Tarng DC, Wang CY, Chen LK*. Effect of frailty on effectiveness and safety of GLP-1 receptor agonists versus SGLT2 inhibitors in people with type 2 diabetes in Taiwan: a retrospective, nationwide, longitudinal study. *Lancet Healthy Longev* 2024 Sep;5(9):100621. (IF:13.4)
8. ^{2,5}Hussein HR, Chang CY, Zheng YN, Yang CY, Li LH, Lee YT, Chen JY, Liang YC, Lin CJ, Chang YC, Geo HN, Noor SM, Kiew LV, Chen FR, Chang CC*. Immune-stealth VP28-conjugated heparin nanoparticles for enhanced and reversible anticoagulation. *Nanotechnology* 2024;35(17):175102. (IF: 2.9)
9. ^{2,4}Lee DY, Chen T, Huang WC*, Chou RH, Wu CH*, Yang CY*, Lee CY, Lin CC, Tarng DC. Systemic vascular resistance predicts high-output cardiac failure in patients with high-flow arteriovenous fistula. *ESC Heart Fail* 2024;11(1):189-197. (IF: 3.2)

10. ^{2,4}Lee DY, Huang WC*, Wu CH*, Yang CY*. Non-invasively assessed hemodynamics in patients with high flow arteriovenous fistula and high output cardiac failure'. *ESC Heart Fail* 2024;11(3):1810-1811. (IF: 3.2)
11. ²Lee KH, Lin YC, Tsai MT, Tu CF, Ou SM, Chen HY, Li FA, Tseng WC, Lin YP, Yang RB*, Tarng DC*. Plasma SCUBE2 as a novel biomarker associates with survival outcomes in patients with sepsis-associated acute kidney injury. *J Microbiol Immunol Infect* 2024;57(5):720-729. (IF: 4.5)
12. ²Lee WC, Tsai CK, Li SY*. Unusual Coincidence: Concurrent Cast Nephropathy and Lymphoma Infiltration in an Influenza A-Associated Acute Kidney Injury. *Case Reports in Nephrology* 2024:1-4. (IF: 0.7)
13. ^{2,5}Li MC, Chang PY, Luo HR, Chang LY, Lin CY, Yang CY*, Lee OKS, Lee YHW, Tarng DC. Functioning tailor-made 3D-printed vascular graft for hemodialysis. *J Vasc Access* 2024;25(1):244-253. (IF: 1.6)
14. ²Li SY, Tsai MT, Kuo YM, Yang HM, Tong ZJ, Cheng HW, Lin CC*, Wang HT*. Aldehyde dehydrogenase 2 preserves kidney function by countering acrolein induced metabolic and mitochondrial dysfunction. *JCI Insight* 2024;9(19):e179871. (IF: 6.3)
15. ²Liao YR, Tsai YC, Hsieh TH, Tsai MT, Lin FY, Lin SJ, Lin CC, Chiang HY, Chu PH*, Li SY*. FHL2 in arterial medial calcification in chronic kidney disease. *Nephrol Dial Transplant* 2024;39(12):2025-2039. (IF: 4.8)
16. ^{2,5}Liu WS, Liang SS, Cheng MM, Wu MT, Li SY, Cheng TT, Liu TY, Tsai CY, Lai YT, Lin CH, Wang HT, Tsou HH*. How renal toxins respond to renal function deterioration and oral toxic adsorbent in pH-controlled releasing capsule. *Environ Toxicol* 2024;39(7):3930-3943. (IF: 4.4)
17. ^{2,5}Liu YA, Yang CY*, Tarng DC. Challenges in pig-to-human kidney xenotransplantation. *Lancet* 2024;403(10444):2595. (IF:98.4)
18. ^{2,4}Sun YS, Huang DF, Chang FP, Chen WS, Liao HT, Chen MH, Tsai HC, Tsai MT, Tsai CY, Lai CC*, Yang CY*. Interstitial fibrosis increases the risk of end-stage kidney disease in patients with lupus nephritis. *RHEUMATOLOGY* 2024;63(9):2467-2472. (IF: 4.7)
19. ^{2,4}Sun YS, Huang DF, Chen WS, Liao HT, Chen MH, Tsai HC, Tsai MT, Tsai CY, Lai CC*, Yang CY*. Real-world risk factors for herpes zoster in patients with rheumatoid arthritis undergoing tofacitinib treatment. *J Chin Med Assoc* 2024;87(11):988-992. (IF: 1.9)
20. ^{2,4}Sun YS, Huang DF, Chen WS, Liao HT, Chen MH, Tsai MT, Yang CY, Lai CC*, Tsai CY*. Risk Factors and Incidence of Serious Infections in Patients With Systemic Lupus Erythematosus Undergoing Rituximab Therapy. *J Rheumatol* 2024;51(2): 160-167. (IF: 3.6)
21. ²Tsai MT, Lin YS, Huang SS, Weng SC, Yang CY, Lee KH, Ou SM, Lin YP, Huang CC, Tseng WC*, Tarng DC*. Physical activity modifies cognitive impairment- associated mortality risks among chronic kidney disease. *J Affect Disord* 2024;366():354-363. (IF: 4.9)
22. ²Tsai MT, Ou SM, Lee KH, Lin CC, Li SY*. Circulating Activin A Kidney Fibrosis and Adverse Events. *Clin J Am Soc Nephrol* 2024;19(2):169-177. (IF: 8.5)
23. ²Tsai MT, Tseng WC, Lee KH, Lin CC, Ou SM*, Li SY*. Associations of urinary fetuin-A with histopathology and kidney events in biopsy-proven kidney disease. *Clin Kidney J* 2024;17(4):sfac065. (IF: 3.9)
24. ²Tsai YC, Hsieh TH, Liao YR, Tsai MT, Lin TP, Lee DY, Park J, Kim D, Susztak K, Yang SF, Lin CC, Li SY*. METTL3-Mediated N⁶-Methyladenosine mRNA Modification and cGAS-STING Pathway Activity in Kidney Fibrosis. *J Am Soc Nephrol* 2024;35(10):1312-1329. (IF: 10.3)
25. ²Tsai YL, Chung MH, Lin NC, Chen CY, Lin YP, Tsai MT, Tsai HL, Chen YA, Ou SM*, Chu CJ, Wu TH*, Tsai CY. The Risk Factors and Clinical Outcomes in Hepatitis B Seropositive and Seronegative Renal Transplant Patients. *Am J Nephrol* 2024;55(4):477-486. (IF: 4.3)

26. ^{2,4}Tseng CH, Hu YA, Chen YT, Yu WC, Lin CC, Li SY*. Beyond prevalence: significance and differential impact of echocardiographic abnormalities in dialysis patients. *J Nephrol* 2024;37(5):1261-1271. (IF: 2.7)
27. ²Wang PH, Kuo NR, Yang CY*, Tarng DC. Unceasing Enzymatic Erosion of the Iliac Artery. *Prog Transplant* 2024;34(4):213-215. (IF: 0.6)
28. ^{1,5}Yen PW, Chen YA, Wang W, Mao FS, Chao CT*, Chiang CK, Lin SH, Tarng DC, Chiu YW, Wu MJ, Chen YC, Kao JTW, Wu MS, Lin CL, Huang JW*, Hung KY*. The screening diagnosis and management of patients with autosomal dominant polycystic kidney disease: A national consensus statement from Taiwan. *Nephrology* 2024;29(5): 245-258. (IF: 2.4)

Hematology

1. ^{2,4}Chang KJ, Shiau LY, Lin SC, Cheong HP, Wang CY, Ma C, Liang YW, Yang YP, Ko PS, Hsu CH, Chiou SH*. N6-methyladenosine and its epitranscriptomic effects on hematopoietic stem cell regulation and leukemogenesis. *Mol Med* 2024;30:196. (IF: 6.0)
2. ^{2,4}Chien SH, Huang HY, Chen YJ, Tsai YC, Lu SH, Lee LH, Liu HM, Chen WC, Liu YC, Lin TA, Liu CY*. Comparing transfusion reactions between pre-storage and post-storage leukoreduced apheresis platelets: an analysis using propensity score matching. *Ann Hematol* 2024;103(4):1389-1396. (IF: 3.0)
3. ^{2,4}Hsu TL, Tsai CK, Liu CY, Yeh CM, Lin FL, Hsiao LT, Liu YC, Chien SH, Wang HY, Ko PS, Lin TN, Chen WC, Chen PM, Liu JH, Gau JP, Liu CJ*. Risk factors of early disease progression and decreased survival for multiple myeloma patients after upfront autologous stem cell transplantation. *Ann Hematol* 2024;103(8):2893-2904. (IF: 3.0)
4. ^{2,4}Hu YW, Yeh CM, Liu CJ, Chen TJ, Huang N, Chou YJ*. Severity of Complications and Duration of Type 2 Diabetes and the Risk of Cancer: A Population-Based Study. *Cancer Epidemiol Biomarkers Prev* 2024;33(5):739-748. (IF: 3.7)
5. ^{2,4}Huang JP, Yeh CM, Gong YW, Tsai MH, Lin YT, Tsai CK*, Liu CJ*. Risk and impact of cytomegalovirus infection in lymphoma patients treated with bendamustine. *Ann Hematol* 2024;103(10):4099-4109. (IF: 3.0)
6. ^{2,4}Huang YC, Hsiao FY, Guan ST, Yao M, Liu CJ, Chen TT, Lin TL, Liu YC, Chen TY, Hong YC, Ma MC, Tan TD, Wang CC, Wu YY, Liao PW, Wu YF, Chen YY, Yu YB, Hsieh YY, Lee MY, Liu JH, Lin SW*, Ko BS*. Ten-year epidemiology and risk factors of cytomegalovirus infection in hematopoietic stem cell transplantation patients in Taiwan. *J Microbiol Immunol Infect* 2024;57(3):365-374. (IF: 4.5)
7. ^{2,4}Kuo MC, Lin CC, Lin HY, Gau JP, Wang MC, Chang MC, Chen TC, Yeh SP, Chen YC, Huang CE, Chiang IJ, Cheng HW, Lee YM, Ku FC, Chang CS*. Safety and effectiveness of ruxolitinib in real-world patients with myelofibrosis: A 2-year observational study from Taiwan. *Leuk Res* 2024;147:107601. (IF: 2.1)
8. ^{2,4}Liao HT*, Lin TA, Liao JT. IgG4-related proctitis parotitis and multiple clustered lymphadenopathy. *Joint Bone Spine* 2024;91(5):105740. (IF: 3.8)
9. ^{2,4}Wu CY, Yeh CM, Tsai CK*, Liu CJ*. The influence of hospital volume and physician volume on early mortality in acute promyelocytic leukemia patients. *Ann Hematol* 2024;103(5):1577-1586. (IF: 3.0)

10. ^{2,4}Yang TH, Tsai CK, Wang HY, Ko PS, Chien SH, Lin TA, Chen WC, Hsu TL, Yeh CM, Lu C, Lin WJ, Chen YJ, Liu CJ*, Liu CY*. Early prediction of platelet recovery with immature platelet fraction in patients receiving hematopoietic stem cell transplantation. *Ann Hematol* 2024;103(11):4661-4670. (IF: 3.0)
11. ^{2,4} Wang CY, Lin SC, Chang KJ, Cheong HP, Wu SR, Lee CH, Chuang MW, Chiou SH, Hsu CH*, Ko PS*. Immunoediting in acute myeloid leukemia: Reappraising T cell exhaustion and the aberrant antigen processing machinery in leukemogenesis. *Heliyon*. 2024;10:e39731. (IF: 3.4)

Allergy, Immunology and Rheumatology

1. ^{1,5}Chang DW, Wu CC, Liu FL, Lu CC, Chu CC, Chang DM*. Fetal microchimerism cells suppress arthritis progression by inducing CD14+IL-10+cells in pregnant experimental mice. *Int J Rheum Dis* 2024;27(9):e15322. (IF: 2.4)
2. ^{1,5}Chuang HC, Lan KY, Hsu PM, Chen MH, Chen YM, Yen JH, Liao BY*, Tan TH*. UHRF1P contributes to IL-17A-mediated systemic lupus erythematosus via UHRF1-MAP4K3 axis. *J Autoimmun* 2024;146:103221. (IF: 7.9)
3. ²Kuo PH, Chang FP, Chen CH, Liao HT*. Saddle nose deformity in eosinophilic granulomatosis with polyangiitis. *Joint Bone Spine* 2024;91(6):105765. (IF: 3.8)
4. ^{2,5}Li TH, Su CF, Lai CC, Chang YF, Wu FY, Chang YS*, Chuang CC, Tsai CY. Epidemiology and risk factors for cytomegalovirus disease in autoimmune inflammatory rheumatic diseases: A nationwide population-based study in Taiwan. *Int J Rheum Dis* 2024;27(2):e15067. (IF: 2.4)
5. ²Liao HT*, Chen CH. Bruton's Tyrosine Kinase in Ankylosing Spondylitis. *SPINE* 2024;49(10):677-681. (IF: 2.7)
6. ²Liao HT*, Lin TA, Liao JT. IgG4-related protosis parotitis and multiple clustered lymphadenopathy. *Joint Bone Spine* 2024;91(5):105740. (IF: 3.8)
7. ^{2,5}Lin HC, Yen CM, Chen WS, Hsu CC, Kung YY, Wu JH, Su YT, Chen KF, Chen HY, Lien CM, Wang MJ, Chang CM*. Unveiling the age-related dynamics in Sjogren's syndrome: Insights from heart rate variability and autonomic function. *Int J Rheum Dis* 2024;27(3):e15088. (IF: 2.4)
8. ^{2,5}Liu WC, Chang CM, Zhang YF, Liao HT*, Chang WC*. Dynamics of T-cell receptor repertoire in patients with ankylosing spondylitis after biologic therapy. *Int Immunopharmacol* 2024;127():111342. (IF: 4.8)
9. ²Ou TS, Sun YS, Lai CC, Chen WS, Tsai HC, Chen MH, Chou CT, Chang FP, Peng YC, Tsai CC, Liao HT*, Tsai CY. Immune-mediated diseases after vaccinations with AZD1222 BNT-162b2 &/or mRNA-1273: An observational investigation of 78 patients. *Int Immunopharmacol* 2024;127:111455. (IF: 4.8)
10. ²Sun YS, Huang DF, Chang FP, Chen WS, Liao HT, Chen MH, Tsai HC, Tsai MT, Tsai CY, Lai CC*, Yang CY*. Interstitial fibrosis increases the risk of end-stage kidney disease in patients with lupus nephritis. *Rheumatology* 2024;63(9):2467-2472. (IF: 4.7)

11. ²Sun YS, Huang DF, Chen WS, Liao HT, Chen MH, Tsai HC, Tsai MT, Tsai CY, Lai CC*, Yang CY*. Real-world risk factors for herpes zoster in patients with rheumatoid arthritis undergoing tofacitinib treatment. *J Chin Med Assoc* 2024;87(11):988-992. (IF: 1.9)
12. ²Sun YS, Huang DF, Chen WS, Liao HT, Chen MH, Tsai MT, Yang CY, Lai CC*, Tsai CY*. Risk Factors and Incidence of Serious Infections in Patients With Systemic Lupus Erythematosus Undergoing Rituximab Therapy. *J Rheumatol* 2024;51(2):160-167. (IF: 3.6)
13. ²Tsai HC, Chen WS, Sun YS, Lai CC, Yang YY, Chou WR, Liao HT*, Tsai CY*, Chou CT. Antibodies against Small Ubiquitin-like Modifier Activating Enzyme May Be a Protective Factor from Rapid Progressive Interstitial Lung Disease in Patients Bearing Antibodies against Melanoma Differentiation Associated Gene 5. *J Clin Med* 2024;13(3):725. (IF: 3.0)
14. ²Tsai HC, Liao HT, Chen WS, Lai CC, Sun YS, Hsu TS*, Chen MH*. Reduced Deltex1 expression in T cells indicates increased disease activity in Sjogren's disease. *Clin Exp Rheumatol* 2024;42(12):2459-2467. (IF: 3.4)
15. ^{1,5}Tsai MK, Chen YL, Chen HC, Liu FC, Chang DM, Lu CC*. IgG4-related tubulointerstitial nephritis. *Ann Rheum Dis* 2024;83(4):537-538. (IF: 20.3)
16. ^{2,5}Wang KC, Sun YS, Tsai HC, Liao HT, Lai CC, Chen WS, Lu LY, Chen MH*. Increased risk of malignancy in HLA-B27-positive patients with ankylosing spondylitis requiring biologics for sustained inflammation: A long-term single-center retrospective study. *Mod Rheumatol* 2024;34(5):1027-1035. (IF: 1.8)
17. ^{2,5}Yen CM, Lin HC, Chen WS, Hsu CC, Liaw CC, Kung YY, Ma CP, Chen HY, Su YT, Chang CM*. Evaluation of traditional Chinese medicine tea bag TBDESJS in patients with Sjogren's syndrome and dry eye syndrome: A phase II pilot study. *Int J Rheum Dis* 2024;27(11):e15398. (IF: 2.4)

Transfusion Medicine

1. ^{2,5}Chan PW, Yu H, Hsu CH*, Liu CY*. Characteristics of early short-term traditional Chinese medicine in breast cancer patients: A population-based cohort study. *J Chin Med Assoc* 2024;87(1):70-78. (IF: 1.9)
2. ^{2,5}Chang MC, Wu PF, Ho YC, Lin WY, Wu CY, Liu SY, Liu CJ*, Lin YT*. Clinical outcomes and safety of remdesivir in hospitalized individuals with COVID-19 with or without severe renal impairment. *J Infect Public Health* 2024;17(7):102460. (IF: 4.7)
3. ^{2,5}Chen BF, Tsai YF, Lien PJ, Lin YS, Feng CJ, Chen YJ, Cheng HF, Liu CY, Chao TC, Lai JI, Tseng LM*, Huang CC*. Prevalent landscape of tumor genomic alterations of luminal B1 breast cancers using a comprehensive genomic profiling assay in Taiwan. *Breast Cancer* 2024;31(2):217-227. (IF: 4.0)
4. ^{2,5}Chien CY, Lee YL, Jeng MJ, Liu CJ*. Using computed tomography to evaluate anatomic landmarks in Taiwanese trauma patients for insertion of resuscitative endovascular balloon occlusion of the aorta: a retrospective cohort study. *Int J Surg* 2024;110(12):7900-7908. (IF: 12.5)
5. ²Chien SH, Huang HY, Chen YJ, Tsai YC, Lu SH, Lee LH, Liu HM, Chen WC, Liu YC, Lin TA, Liu CY*. Comparing transfusion reactions between pre-storage and post-storage leukoreduced apheresis platelets: an analysis using propensity score matching. *Ann Hematol* 2024;103(4):1389-1396. (IF: 3.0)

6. ^{2,5}Ho IW, Pan YL, Lai J, Liu CY*. Characteristics and outcome of systemic treatment for metastatic or unresectable thymic carcinoma: A single institution experience. *Thorac Cancer* 2024;15(4):339-346. (IF: 2.3)
7. ^{2,5}Hsu TL, Tsai CK, Liu CY, Yeh CM, Lin FL, Hsiao LT, Liu YC, Chien SH, Wang HY, Ko PS, Lin TN, Chen WC, Chen PM, Liu JH, Gau JP, Liu CJ*. Risk factors of early disease progression and decreased survival for multiple myeloma patients after upfront autologous stem cell transplantation. *Ann Hematol* 2024;103(8):2893-2904. (IF: 3.0)
8. ^{2,5}Huang HW, Liu CY, Tung TH, Liu LN*. Effects of hospice-shared care on terminal cancer patients in Taiwan: A hospital-based observational study. *Eur J Oncol Nurs* 2024;69:102525. (IF: 2.7)
9. ^{2,5}Huang JP, Yeh CM, Gong YW, Tsai MH, Lin YT, Tsai CK*, Liu CJ*. Risk and impact of cytomegalovirus infection in lymphoma patients treated with bendamustine. *Ann Hematol* 2024;103(10):4099-4109. (IF: 3.0)
10. ^{2,5}Lai JI*, Kuo TH, Huang KJ, Chai LMX, Lee MH, Liu CY, Tsai YF, Huang CC, Tseng LM, Hsu CC*, Chao TC. Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients. *Oncologist* 2024;29(4):e455-e466. (IF: 4.8)
11. ^{2,5}Lai TY, Hu YW, Wang TH, Chen JP, Shiau CY, Huang P, Lai IC, Liu YM, Huang CC, Tseng LM, Huang N, Liu CJ*. Estimating the risk of major adverse cardiac events following radiotherapy for left breast cancer using a modified generalized Lyman normal-tissue complication probability model. *Breast* 2024;77:103788. (IF: 5.7)
12. ^{2,5}Lee CY, Yu TY, Lin FL, Hung GY, Hou MH, Ho CY, Liu CY, Chiou TJ, Yen HJ*. Peripheral blood stem cell harvesting in young children weighing less than 15 kg. *Cytotherapy* 2024;26(10):1201-1209. (IF: 3.7)
13. ^{3,5}Li YJ*, Chien SH, Huang R, Herrmann A, Zhao QQ, Li PC, Zhang CY, Martincuks A, Santiago NL, Zong K, Swiderski P, Okimoto RA, Song MH, Rodriguez L, Forman SJ, Wang XL, Yu H*. A platform to deliver single and bi-specific Cas9/guide RNA to perturb genes *in vitro* and *in vivo*. *Mol Ther* 2024;32(10):3629-3649. (IF: 12.1)
14. ^{2,5}Tsai YF, Huang CC, Hsu CY, Feng CJ, Lin YS, Chao TC, Lai J, Lien PJ, Liu CY, Chiu JH*, Tseng LM. Genomic Alterations of Tumors in HER2-Low Breast Cancers. *Int J Mol Sci* 2024;25(2):1318. (IF: 4.9)
15. ²Yang TH, Tsai CK, Wang HY, Ko PS, Chien SH, Lin TA, Chen WC, Hsu TL, Yeh CM, Lu C, Lin WJ, Chen YJ, Liu CJ*, Liu CY*. Early prediction of platelet recovery with immature platelet fraction in patients receiving hematopoietic stem cell transplantation. *Ann Hematol* 2024;103(11):4661-4670. (IF: 3.0)
16. ^{2,5}Yeh CM, Lai TY, Hu YW, Teng CJ, Huang N*, Liu CJ*. The impact of surgical volume on outcomes in newly diagnosed colorectal cancer patients receiving definitive surgeries. *Sci Rep* 2024;14(1):8227. (IF: 3.8)

General Medicine

1. ^{2,4}Chang CC, Huang HC*, Hsu SJ*, Pun CK, Chuang CL, Hou MC, Lee FY. Ezetimibe treatment reduces oxidized low-density lipoprotein in biliary cirrhotic rats. *J Chin Med Assoc* 2024;87(5):463-470. (IF: 1.9)

2. ^{2,4}Chang CC*, Sung WT, Lu YW, Chuang MJ, Lee YH, Tsai YL, Chou RH, Huang SS, Huang PH*. Real-World Clinical Performance of a Novolimus-Eluting Stent Versus a Sirolimus-Eluting Stent. *Clin Cardiol* 2024;47(7):e24317. (IF: 2.4)
3. ^{2,4}Chao CJ, Jeong J, Arsanjani R, Kim K, Tsai YL, Yu WC, Farina JM, Mahmoud AK, Ayoub C, Grogan M, Kane GC, Banerjee I, Oh JK*. Echocardiography-Based Deep Learning Model to Differentiate Constrictive Pericarditis and Restrictive Cardiomyopathy. *JACC-Cardiovasc Imag* 2024;17(4):349-360. (IF: 14.0)
4. ^{2,4}Chen WT, Chung FP*, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chao TF, Liao JN, Lin CY, Chang TY, Kuo L, Wu C, Liu CM, Liu SH, Hsieh YC, Li CH, Chen SA. Lower contact force predicts right pulmonary vein carina breakthrough after ablation index-guided pulmonary vein isolation using high-power short-duration. *J Cardiovasc Electrophysiol* 2024;35(1):60-68. (IF: 2.7)
5. ²Ho CT, Fu CC, Tan ECH*, Kao WY, Lee PC, Huang YH, Huo TI, Hou MC, Wu JC, Su CW*. The association between proton-pump inhibitor use and recurrence of hepatocellular carcinoma after hepatectomy. *J Gastroenterol Hepatol* 2024;39(10):2077-2087. (IF: 3.7)
6. ²Ho CT, Tan ECH, Lee PC, Chu CJ, Huang YH, Huo TI, Hou MC, Wu JC, Su CW*. Prognostic Nutritional Index as a Prognostic Factor for Very Early-Stage Hepatocellular Carcinoma. *Clin Transl Gastroenterol* 2024;15(4):e00678. (IF: 3.0)
7. ²Ho CT, Tan ECH*, Lee PC, Chu CJ, Huang YH, Huo TI, Su YH, Hou MC, Wu JC, Su CW*. Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma. *Clin Mol Hepatol* 2024;30(3):406-420. (IF: 14.0)
8. ²Ho CT, Tan ECH*, Su CW. Correspondence to editorial on "Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma". *Clin Mol Hepatol* 2024;30(4):1016-1018. (IF: 14.0)
9. ²Ho CT*, Tan EH, Lee PC, Su CW. Reply to "Association between proton-pump inhibitor use and recurrence of hepatocellular carcinoma after hepatectomy: concerns to be addressed". *J Gastroenterol Hepatol* 2024;39(12):2942-2942. (IF: 3.7)
10. ^{2,4}Hsiao YW, Lin WL, Chou YH, Liu SH, Liao TWE, Chen SA*, Lo LW*. Renal sympathetic denervation ameliorates the activated inflammatory response through JAK-STAT pathway in a chronic obstructive sleep apnea animal model. *Sleep Med* 2024;113():142-151. (IF: 4.8)
11. ^{2,4}Hsu CJ, Wu CI*, Lin YJ. A Case with a Short QT Interval and Idiopathic Ventricular Fibrillation Due to Carnitine Transporter Defect. *Acta Cardiol Sin* 2024;40(6):801-804. (IF: 1.8)
12. ^{2,4}Hsu SJ, Yang KY, Huang HC, Chuang CL, Chang CC*, Pun CK, Hou MC, Lee FY. Pre-treatment with tocilizumab reduces lipopolysaccharide-induced acute lung injury in biliary cirrhotic rats. *Eur J Pharmacol* 2024;980:176817. (IF: 4.2)
13. ^{2,5}Huang CC, Yeh HY, Lin R, Liao TL, Shen HC, Yang YY*, Lin HC. Inhibition of visceral adipose tissue-derived pathogenic signals by activation of adenosine A_{2A}R improves hepatic and cardiac dysfunction of NASH mice. *Am J Physiol-Gastroint Liver Physiol* 2024;326(4):G385-G397. (IF: 3.9)
14. ^{2,4}Kuo L, Wang GJ, Chang SL, Lin YJ, Chung FP, Lo LW, Hu YF, Chao TF, Tuan TC, Liao JN, Chang TY, Lin CY, Liu CM, Liu SH, Kuo MR, Li GY, Huang YS, Wu C, Chen SA*, Lu

- CF*. Feasibility of Auto-Quantified Epicardial Adipose Tissue in Predicting Atrial Fibrillation Recurrence After Catheter Ablation. *Circ J* 2024;88(7):1089-1098. (IF: 3.1)
15. ^{2,4}Lee DY, Chang CC, Ko CF, Lee YH, Tsai YL, Chou RH, Chang TY, Guo SM*, Huang PH*. Artificial intelligence evaluation of coronary computed tomography angiography for coronary stenosis classification and diagnosis. *Eur J Clin Invest* 2024;54(1):e14089. (IF: 5.5)
 16. ^{2,4}Lin WL, Hsiao YW, Liu SH, Cheng WH, Tsai TY, Chou YH, Yang CCH, Kuo TBJ, Chen SA, Lo LW*. Effects of low-density lipoprotein cholesterol on sleep apnea: Insights from a rat model of cardiovascular autonomic dysregulation. *Sleep Med* 2024;115():76-82. (IF: 4.8)
 17. ^{2,5}Lin YH, Wang CH, Huang YH, Shen HC, Wu WK, Yeh HY, Huang CC, Su CW, Yang YY*, Wu MS, Lin HC, Hou MC. Models incorporating physical laboratory and gut metabolite markers can be used to predict severe hepatic steatosis in MAFLD patients. *Kaohsiung J Med Sci* 2024;40(12):1095-1105. (IF: 2.7)
 18. ^{2,5}Lu CH, Wang W, Li YCJ, Chang IW, Chen CL, Su CW, Chang CC, Kao WY*. Machine Learning Models for Predicting Significant Liver Fibrosis in Patients with Severe Obesity and Nonalcoholic Fatty Liver Disease. *Obes Surg* 2024;34 (12):4393-4404. (IF: 2.9)
 19. ^{2,4}Luan CH, Su PS, Chu CJ*, Lin CC, Su CW, Luo JC, Lee IC, Chi CT, Lee SD, Wang YJ, Lee FY, Huang YH, Hou MC. Analyzing risk factors and developing a stratification system for hepatocellular carcinoma recurrence after interferon-free direct-acting antiviral therapy in chronic hepatitis C patients. *J Chin Med Assoc* 2024;87(4):357-368. (IF: 1.9)
 20. ^{2,4}Nguyen DSN, Lin CY*, Chung FP, Chang TY, Lo LW, Lin YJ, Chang SL, Hu YF, Tuan TC, Chao TF, Liao JN, Kuo L, Liu CM, Liu SH, Wu C, Kuo MJ, Li GY, Huang YS, Wu SJ, Siow YK, Bautista JAL, Cao DT, Chen SA. Signal-averaged electrocardiography as a noninvasive tool for evaluating the ventricular substrate in patients with nonischemic cardiomyopathy: reassessment of an old tool. *Front Cardiovasc Med* 2024;11:1306055. (IF: 3.6)
 21. ⁵Peng KW, Chang ML, Chien RN, Chen YC, Tian YC, Peng YS, Huang HC, Fang JT, Lee FY, Yang CW, Tsai MH*. Pulmonary Vascular Permeability and Extravascular Lung Water Index in Patients with Liver Cirrhosis and Septic Shock. *J Clin Med* 2024;13(13):3796. (IF: 3.0)
 22. ^{2,4}Pun CK, Huang HC, Chang CC, Chuang CL, Hsu SJ*, Hou MC, Lee FY. Fructooligosaccharides reverses hepatic vascular dysfunction and dysbiosis in rats with liver cirrhosis and portal hypertension. *Eur J Clin Invest* 2024;54(11):e14287. (IF: 4.4)
 23. ^{2,4}Pun CK, Huang HC, Chang CC, Hsu SJ*, Chuang CL, Huang YH, Hou MC, Lee FY. Low-dose alcohol exacerbates hyperdynamic circulation and shunting in non-alcoholic cirrhotic rats. *Biosci Rep* 2024;44(7):BSR20240354. (IF: 3.8)
 24. ^{2,4}Siow YK, Lin CY*, Chung FP, Lin YJ, Chang SL, Lo LW, Hu YF, Liao JN, Chang TY, Tuan TC, Kuo L, Wu C, Liu CM, Liu SH, Li GY, Kuo MJ, Wu SJ, Bautista JA, Huang YS, Nguyen DSN, Chen SA. Catheter ablation in patients with atrial fibrillation and dilated cardiomyopathy. *Front Cardiovasc Med* 2024;11:1305485. (IF: 3.6)
 25. ²Su CW, Ochirkhuree B, Namdag B, Badamnachin B, Ganbold S, Gidaagaya S, Ganbold A, Yang SS, Duger D*, Wu JC*. Risk factors associated with hepatitis D virus infection and preventive strategies in Mongolia. *J Chin Med Assoc* 2024;87(5):480-487. (IF: 1.9)

26. ^{2,4}Sung WT, Chuang MJ, Tsai YL, Chou RH, Chang CC*, Huang PH*. Impacts of the SYNTAX score I II and SYNTAX score II 2020 on left main revascularization. *Sci Rep* 2024;14(1):1073. (IF: 4.6)
27. ^{2,5}Teng W, Chang TT, Yang H, Peng CY, Su CW, Su TH, Hu TH, Yu ML, Yang HC, Wu JC*. Correction to: Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines (vol 15 pg 1421 2021). *Hepatol Int* 2024;18(3):1066. (IF: 6.6)
28. ⁵Weng CJ, Li CH, Lin YJ, Chang SL, Hu YF, Chung FP, Liao JN, Tuan TC, Chao TF, Lin CY, Chang TY, Liu CM, Liu SH, Chen WT, Chang WH, Chuong NKT, Kuo MR, Kao PH, Li GY, Ahliah I, Chen SA*, Lo LW*. Skin sympathetic nerve activity in different ablation settings for atrial fi brillation. *J Cardiol* 2024;83(5):306-312. (IF: 2.5)

Endoscopy Diagnosis and Treatment

1. ²Chang TE, Huang KH, Luo JC*, Huang YH, Lin HH, Fang WL, Hou MC. The alteration of fecal microbial and metabolic profile of gallstone patients in Taiwan: Single-center study. *J Chin Med Assoc* 2024;87(6):572-580. (IF: 1.9)
2. ^{2,5}Chang WK, Peng CL, Chen YW, Sun CK, Chen CC, Liu TC, Chu YY, Tsai IF, Chung CS, Lin HF, Hsu FY, Tai WC, Lee HC, Yen HH, Wang EM, Chen SH, Chu CH, Chen MJ, Lu CL, Chiu CT*. Recommendations and guidelines for endoscope reprocessing: Current position statement of digestive endoscopic society of Taiwan. *J Microbiol Immunol Infect* 2024;57(2):211-224. (IF: 4.5)
3. ¹Chen HY, Tu MH*, Chen MY. Effectiveness of a Mobile Health Application for Educating Outpatients about Bowel Preparation. *Healthcare* 2024;12(14):1374. (IF: 2.4)
4. ^{2,5}Chen WC, Yang TC, Lee PC, Wang YP, Hou MC*, Lee FY. A Randomized Controlled Trial of Propranolol Use During Ligation Program for Secondary Prophylaxis of Esophageal Variceal Bleeding. *Am J Gastroenterol* 2024;119(2):278-286. (IF: 8.5)
5. ^{2,4}Hsu SJ, Yang KY, Huang HC, Chuang CL, Chang CC, Pun CK, Hou MC, Lee FY. Pre-treatment with tocilizumab reduces lipopolysaccharide-induced acute lung injury in biliary cirrhotic rats. *Eur J Pharmacol* 2024;980:176817. (IF: 4.2)
6. ^{2,5}Kim DS, Yoon YI, Kim BK, Choudhury A, Kulkarni A, Park JY, Kim J, Sinn DH, Joo DJ, Choi Y, Lee JH, Choi HJ, Yoon KT, Yim SY, Park CS, Kim DG, Lee HW, Choi WM, Chon YE, Kang WH, Rhu J, Lee JG, Cho Y, Sung PS, Lee HA, Kim JH, Bae SH, Yang JM*, Suh KS*, Al Mahtab M, Tan SS, Abbas Z, Shrestha A, Alam S, Arora A, Kumar A, Rath P, Bhavani R, Panackel C, Lee KC, Li J, Yu ML, George J, Tanwandee T, Hsieh SY, Yong CC, Rela M, Lin HC, Omata M, Sarin SK. Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation. *Hepatol Int* 2024;18(2):299-383. (IF: 5.9)
7. ^{2,4}Li CJ, Lee PC*, Huang KW, Huang KJ, Chang TE, Chang CC, Wang SE, Shyr YM, Li CP, Luo JC, Hou MC. Postoperative prognostic nutrition index predicts survival in patients with small bowel adenocarcinoma after surgical resection. *J Chin Med Assoc* 2024;87(9):819-827. (IF: 1.9)
8. ^{2,4}Li CJ*, Lee PC, Huang KW, Huang KJ, Chang TE, Chang CC, Wang SE, Shyr YM, Li CP, Luo JC, Hou MC. Reply to: Is "postoperative adjuvant chemotherapy" needed for small bowel adenocarcinoma after surgical resection?. *J Chin Med Assoc* 2024;87(12):1099-1100. (IF: 1.9)

9. ²Lin KL, Sung KY, Ye YC, Wang YP*, Chang TE, Wu PS, Luo JC, Hou MC, Lu CL. Prolonged video capsule endoscopy examination durations can improve capsule endoscopy completeness. *BMC Gastroenterol* 2024;24(1):336. (IF: 2.5)
10. ²Low EXS, Wang YP, Lu CL*. Risks of Proton Pump Inhibitors in Patients with Cirrhosis: Please Peruse the Indications. *Dig Dis Sci* 2024;69(1):7-9. (IF: 2.5)
11. ²Low EXS, Wang YP*, Ye YC, Liu PY, Sung KY, Lin HE, Lu CL*. A Comparison between Chicago Classification Versions 3.0 and 4.0 and Their Impact on Manometric Diagnoses in Esophageal High-Resolution Manometry Cases. *Diagnostics* 2024;14(3):263. (IF: 3.0)
12. ^{2,4}Pun CK, Huang HC (equal contribution), Chang CC, Chuang CL, Hsu SJ, Hou MC, Lee FY. Fructooligosaccharides reverses hepatic vascular dysfunction and dysbiosis in rats with liver cirrhosis and portal hypertension. *Eur J Clin Invest* 2024;54:e14287. (IF: 4.4)
13. ^{2,4}Pun CK, Huang HC (equal contribution), Chang CC, Hsu SJ, Chuang CL, Huang YH, Hou MC, Lee FY. Low-dose alcohol exacerbates hyperdynamic circulation and shunting in non-alcoholic cirrhotic rats. *Biosci Rep* 2024;44:BSR20240354. (IF: 3.8)
14. ^{2,4}Pun CK, Huang HC (equal contribution), Chang CC, Hsu SJ, Huang YH, Hou MC, Lee FY. Hepatic encephalopathy: From novel pathogenesis mechanism to emerging treatments. *J Chin Med Assoc* 2024;87:245-51. (IF: 1.9)
15. ^{2,5}Shah A, Lee YY, Suzuki H, Tan-Loh J, Siah KTH, Gwee KA, Fairlie T, Talley NJ, Ghoshal UC, Wang YP, Kim YS, Holtmann G*. A pathophysiologic framework for the overlap of disorders of gut-brain interaction and the role of the gut microbiome. *Gut Microbes* 2024;16(1):2413367. (IF: 12.2)
16. ^{2,5}Tsai CF, Chuang CH, Tu PC, Chang WC, Wang YP, Liu PY, Wu PS, Lin CY, Lu CL*. Interaction of the gut microbiota and brain functional connectivity in late-life depression. *J Psychiatry Neurosci* 2024;49(5):E289-E300. (IF: 4.1)
17. ²Wang YP, Karmakar R, Mukundan A, Tsao YM, Sung TC, Lu CL*, Wang HC*. Spectrum aided vision enhancer enhances mucosal visualization by hyperspectral imaging in capsule endoscopy. *Sci Rep* 2024;14(1):22243. (IF: 3.8)
18. ²Wu PS, Hsieh YC, Lee PC, Yang TC, Chen YJ, Yang YY, Huang HC, Hsu SJ, Huo TI, Lee KC*, Lin HC, Hou MC*. Mac-2-Binding Protein Glycosylation Isomer to Albumin Ratio Predicts Bacterial Infections in Cirrhotic Patients. *Dig Dis* 2024;42(2):166-177. (IF: 2.0)
19. ^{2,4}Yang TC, Chen WC, Hou MC, Chen PH, Lee PC, Chang CY, Lu HS, Chen YJ, Hsu SJ, Huang HC, Luo JC, Huang YH, Lee FY. Endoscopic variceal ligation versus propranolol for the primary prevention of oesophageal variceal bleeding in patients with hepatocellular carcinoma: an open-label, two-centre, randomised controlled trial. *Gut* 2024;73:682-90. (IF: 23)
20. ²Ye YC, Sung KY, Chang TE, Wu PS, Wang YP*, Luo JC, Hou MC, Lu CL. Early double-balloon enteroscopy was not related to better clinical outcomes in patients with suspected overt small bowel bleeding. *J Chin Med Assoc* 2024;87(4):377-383. (IF: 1.9)
21. ²Ye YC, Wang YP*, Chang TE, Wu PS, Hsin IF, Chen PH, Tai SK, Chu PY, Hou MC, Lu CL. Routine image-enhanced endoscopic surveillance for metachronous esophageal squamous cell neoplasms in head and neck cancer patients. *Esophagus* 2024;21(2):131-140. (IF: 2.2)

Holistic and Multidisciplinary Medicine

1. ²Chang CC, Huang HC*, Hsu SJ*, Pun CK, Chuang CL, Hou MC, Lee FY. Ezetimibe treatment reduces oxidized low-density lipoprotein in biliary cirrhotic rats. *J Chin Med Assoc* 2024;87(5):463-470. (IF: 1.9)
2. ^{2,4}Hsiao YW, Lin WL, Chou YH, Liu SH, Liao TWE, Chen SA*, Lo LW*. Renal sympathetic denervation ameliorates the activated inflammatory response through JAK-STAT pathway in a chronic obstructive sleep apnea animal model. *Sleep Med* 2024;113():142-151. (IF: 3.8)
3. ^{2,4}Hsu SJ, Yang KY, Huang HC, Chuang CL, Chang CC*, Pun CK, Hou MC, Lee FY. Pre-treatment with tocilizumab reduces lipopolysaccharide-induced acute lung injury in biliary cirrhotic rats. *Eur J Pharmacol* 2024;980:176817. (IF: 4.2)
4. ^{2,4}Hsu TL, Tsai CK, Liu CY, Yeh CM, Lin FL, Hsiao LT, Liu YC, Chien SH, Wang HY, Ko PS, Lin TN, Chen WC, Chen PM, Liu JH, Gau JP, Liu CJ*. Risk factors of early disease progression and decreased survival for multiple myeloma patients after upfront autologous stem cell transplantation. *Ann Hematol* 2024;103(8):2893-2904. (IF: 3.0)
5. ²Li CJ, Lee PC*, Huang KW, Huang KJ, Chang TE, Chang CC, Wang SE, Shyr YM, Li CP, Luo JC, Hou MC. Postoperative prognostic nutrition index predicts survival in patients with small bowel adenocarcinoma after surgical resection. *J Chin Med Assoc* 2024;87(9):819-827. (IF: 1.9)
6. ²Li CJ*, Lee PC, Huang KW, Huang KJ, Chang TE, Chang CC, Wang SE, Shyr YM, Li CP, Luo JC, Hou MC. Reply to: Is "postoperative adjuvant chemotherapy" needed for small bowel adenocarcinoma after surgical resection?. *J Chin Med Assoc* 2024;87(12):1099-1100. (IF: 1.9)
7. ^{2,4}Pun CK, Huang HC, Chang CC, Chuang CL, Hsu SJ*, Hou MC, Lee FY. Fructooligosaccharides reverses hepatic vascular dysfunction and dysbiosis in rats with liver cirrhosis and portal hypertension. *Eur J Clin Invest* 2024;54(11):e14287. (IF: 4.4)
8. ^{2,4}Pun CK, Huang HC, Chang CC, Hsu SJ*, Chuang CL, Huang YH, Hou MC, Lee FY. Low-dose alcohol exacerbates hyperdynamic circulation and shunting in non-alcoholic cirrhotic rats. *Biosci Rep* 2024;44(7):BSR20240354. (IF: 3.8)
9. ^{2,4}Pun CK, Huang HC, Chang CC, Hsu SJ*, Huang YH, Hou MC, Lee FY. Hepatic encephalopathy: From novel pathogenesis mechanism to emerging treatments. *J Chin Med Assoc* 2024;87(3):245-251. (IF: 1.9)
10. ^{2,4}Su CW, Ochirkhuree B, Namdag B, Badamnachin B, Ganbold S, Gidaagaya S, Ganbold A, Yang SS, Duger D*, Wu JC*. Risk factors associated with hepatitis D virus infection and preventive strategies in Mongolia. *J Chin Med Assoc* 2024;87(5):480-487. (IF: 1.9)
11. ²Tseng CH, Hu YA, Chen YT, Yu WC, Lin CC, Li SY*. Beyond prevalence: significance and differential impact of echocardiographic abnormalities in dialysis patients. *J Nephrol* 2024;37(5):1261-1271. (IF: 2.7)
12. ²Tseng CH, Huang WM, Chang HC, Yu WC, Cheng HM, Chiang CE, Chen CH, Sung SH*. Tissue inhibitor of metalloproteinase (TIMP)-1 predicts failure of recovery of ejection fraction in acute heart failure with reduced ejection fraction. *Open Heart*. 2024 Sep 25;11(2):e002770. (IF=2.8)